



3

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, C07K 14/71, C12N 15/85, 5/10, A61K 48/00, C12Q 1/00		A1	(11) International Publication Number: WO 97/00957
			(43) International Publication Date: 9 January 1997 (09.01.97)
(21) International Application Number: PCT/US96/10725		(81) Designated States: AU, CA, IL, JP, MX, NO, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 21 June 1996 (21.06.96)			
(30) Priority Data:		Published	
08/494,282	23 June 1995 (23.06.95)	US	<i>With international search report.</i>
08/573,692	18 December 1995 (18.12.95)	US	<i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(71) Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US]; 17 Quincy Street, Cambridge, MA 02139 (US).			
(72) Inventors: PATTERSON-WINSTON, Campbell; 1408 Com- monwealth Avenue, Brighon, MA 02135 (US). LEE, Mu- En; 102, Nardell Road, Newton, MA 02159 (US). HABER, Edgar, P.O. Box 161, South Road, Salisbury, NH 03268 (US).			
(74) Agent: FRASER, Janis, K.; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).			

BEST AVAILABLE COPY

(54) Title: TRANSCRIPTIONAL REGULATION OF GENES ENCODING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS

	BamHI		XhoI	HindIII	EcoRI	BamHI				
-15.5kb			+1			+4.7kb				
-780	CCTCCTTCCC	CTGGGGCTAA	<u>GGA</u> TATCTTG	GCTGGAAGCT	CTGCTCTGAA	AAGGGCCATG	GGCAAACTTT	CACTAGGGCT	CTTGTTGGG	GAGCAAGATG
										<i>B</i> Box
-680	GACAAAAGCC	TTCTTGCGGC	TAGGCAGGTC	ACTTCAAAC	TGGAGCCGOC	AAATATTTTG	GGAAATAGCG	GGAAATGCTG	CGAATCGGG	AAGTCGGTTT
										<i>K</i> Box
-580	TCTGATTAA	AGCAACCAGA	TTCAGCTTTT	TAAACTACAA	TTATACTGGC	CAAACAAAAT	ACCCCTATAC	AAAAACAAA	ACTACTGGCA	GGAGTGGCTG
-480	CCAGCTTGCG	ACCGGCATA	CTTGGCTGAG	TATCGGCTTC	TCCTTGTGTC	CTCCAAACTG	<u>CTG</u> CAGATTC	TGGGCCACTT	CAGACGGCGC	CGATGGCGAA
-380	GAGGGTCCTG	CACTTTGACG	CGCTGTGTA	GGGAGCGGTC	CTCTTCGACG	CGCTCTGGT	GATGCTCCCC	AAATTTCCGG	GACCGGCAAG	CGATTAAATC
-280	TTGAGTTGTC	TCAGCGCCCG	TTACCGAGTA	CTTTTATATT	ACACCAGAAA	CAAAGTTGTT	GCTCTGGCAT	GTCTCTCTCT	GGGCGACTTG	GGGCGCAGCG
	<i>B</i> Box									
-180	CAGTCAGTTT	GTGTCGGCGAA	ATCGCGAGAT	GTAAATCGGC	TTGGGAGGCT	GGAGATCCCC	GGCGGTACC	CGCGTGACGG	GGGCGGCTGG	GGCAGCGGCA
	<i>N</i> Box									
-80	GAGGCTCTCC	TGGGCGCGGG	CCCGGCGCGG	CATGGCGCGG	CTTGGCGGCT	CTAGAGTTTC	GGCTCCAGCT	CCCAOCCTGC	ACTGAGTCCC	GGGACCCCGG
+21	GAGAGCGGTC	AGTGTGTGGT	CGCTGGTTT	CCTCTGCTG	CGCGCGGCAT	GACTCTGGCG	CCGCAAGAAC	TCCGTCTGCG	AGCCTCGATA	TCCTCTCTTA
+121	CGGGCACCOC	CAGACGCCCC	<u>TC</u> CAGCGGCC	GGTGGCGGOC	CGGGCTCCCT	AGCCCTGTGC	GCTCAACTGT	CCTGCGCTGC	GGGCTGCGCG	GAGTTCCACC
+221	TCCGCGCCTC	CTTCTCTAGA	CAGGCGCTGG	GAGAAAGAAC	CGGCTCCCGA	GTCTCTGGCA	TTTCGCCCGG	CTCGAGGTGC	AGGATOCAGA	GCAGGCTGCT
+321	GCTGGCGGTC	GGCCTGTGGC	TCTGCGTTCG	GACCGGGGCC	GCTCTGTGTC	gtaaggagcc	cactctggag	gaggaaggca	gacaggttgg	gtgagggggg
	L A V	A L W	L C V E	T R A	A S V (SEQ ID NO: 15)					
+421	agaggaactg	aaagccagat	ctaactogga	atcgtagagc	tgaggagttg	gacaggaatt	gacatttt (SEQ ID NO: 7)			

(57) Abstract

The invention features substantially pure DNA containing an endothelial cell-specific promoter sequence capable of directing endothelial cell-specific transcription of a polypeptide-encoding sequence or an antisense template to which it is operably linked. The invention also features methods for identifying compounds which inhibit or enhance endothelial cell growth.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TC	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

TRANSCRIPTIONAL REGULATION OF GENES ENCODING VASCULAR
ENDOTHELIAL GROWTH FACTOR RECEPTORS

Background of the Invention

5 This invention relates to endothelial cell-specific gene transcription and transcriptional regulation by TNF- α .

 Vascular endothelial growth factor (VEGF) is a potent and specific endothelial cell mitogen (Connolly et
10 al., 1989, J. Clin. Invest. 84:1470-1478; Leung et al., 1989, Science 246:1306-1309). Through interactions with its receptors, Kinase-insert Domain-containing Receptor/fetal liver kinase-1 (KDR/flk-1) and flt1, VEGF plays critical roles in growth and maintenance of
15 vascular endothelial cells and in the development of new blood vessels in physiologic and pathologic states (Aiello et al., 1994, New Engl. J. Med. 331:1480-1487; Shweiki et al., 1992, Nature 359:843-845; Berkman et al., 1993, J. Clin. Invest. 91:153-159). The patterns of
20 embryonic expression of VEGF suggest that it is crucial for differentiation of endothelial cells from hemangioblasts and for development of blood vessels at all stages of growth (Jakeman et al., 1993, Endocrinology 133:848-859; Breier et al., 1992, Development 114:521-
25 532). Among many potentially angiogenic factors, VEGF is the only one with patterns of expression, secretion, and activity that suggest a specific angiogenic function in normal development (Klagsbrun et al., 1993, Current Biology 3:699-702).

30 High-affinity receptors for VEGF are found only on endothelial cells, and VEGF binding has been demonstrated on macro- and microvascular endothelial cells and in quiescent and proliferating endothelial cells (Jakeman et al., 1993, Endocrinology 133:848-859; Jakeman et al.,

- 2 -

1992, Clin. Invest. 89:244-253). The tyrosine kinases KDR/flk-1 and flt1 have been identified as candidate VEGF receptors by affinity cross-linking and competition-binding assays (de Vries et al., 1992, Science 255:989-991; Millauer et al., 1993, Cell 72:835-846; Terman et al., 1992, Biochem. Biophys. Res. Commun. 187:1579-1586). These two receptor tyrosine kinases contain seven similar extracellular immunoglobulin domains and a conserved intracellular tyrosine kinase domain interrupted by a kinase insert (de Vries et al., 1992, Science 255:989-991; Matthews et al., 1991, Proc. Natl. Acad. Sci. U.S.A 88:9026-9030; Terman et al., 1991, Oncogene 6:1677-1683); they are expressed specifically by endothelial cells *in vivo* (Millauer et al., 1993, Cell 72:835-846; Peters et al., 1993, Proc. Natl. Acad. Sci. USA 90:8915-8919; Quinn et al., 1993, Proc. Natl. Acad. Sci. USA 90:7533-7537; Yamaguchi et al., 1993, Development 118:489-498). *In situ* hybridization in the developing mouse has demonstrated that KDR/flk-1 is expressed in endothelial cells at all stages of development, as well as in the blood islands in which endothelial cell precursors first appear (Millauer et al., 1993, Cell 72:835-846). KDR/flk-1 is a marker for endothelial cell precursors at their earliest stages of development (Yamaguchi et al., 1993, Development 118:489-498).

The vascular endothelium is critical for physiologic responses including thrombosis and thrombolysis, lymphocyte and macrophage homing, modulation of the immune response, and regulation of vascular tone. The endothelium is also intimately involved in the pathogenesis of vascular diseases such as atherosclerosis (Ross, 1993, Nature 362:801-809). Although a number of genes expressed in the endothelium have been characterized (Collins et al., 1991, J. Biol.

- 3 -

Chem. 266:2466-2473; Iademarco et al., 1992, J. Biol. Chem. 267:16323-16329; Jahroudi et al., 1994, Mol. Cell. Biol. 14:999-1008; Lee et al., 1990, J. Biol. Chem. 265:10446-10450), expression of these genes is either not
5 limited to vascular endothelium (e.g., the genes encoding von Willebrand factor, endothelin-1, vascular cell adhesion molecule-1), or is restricted to specific subpopulations of endothelial cells (e.g., the gene for endothelial-leukocyte adhesion molecule-1).

10

Summary of the Invention

The invention features substantially pure DNA, i.e., a promoter sequence, which regulates endothelial cell-specific transcription of a polypeptide-encoding sequence to which it is operably linked. The DNA of the
15 invention contains a sequence substantially identical to nucleotides -225 to -164 of the KDR/flk-1 promoter, i.e., 5' TTGTTGCTCTGGGATGTTCTCTCCTGGGCGACTTGGGGCCCAGCGCAGTCCAGT TGTGTGGG 3' (SEQ ID NO:1). By "substantially identical" is meant at least 80% identical to a reference DNA
20 sequence, that is, up to 20% of the basepairs of the reference DNA sequence can be replaced with an alternative basepair (e.g., G-C replaced with A-T, T-A, or C-G), provided that the transcription-promoting activity of the altered sequence is the same or greater
25 than that of the reference sequence. The DNA may also include a sequence substantially identical to nucleotides -95 to -77 of the KDR/flk-1 promoter, i.e., 5' GCTGGCCGCACGGGAGAGC 3' (SEQ ID NO:2), a sequence substantially identical to nucleotides -95 to -60 of the
30 KDR/flk-1 promoter, i.e., 5' GCTGGCCGCACGGGAGAGCCCCTCCTCCGC CCCGGC 3' (SEQ ID NO:3), a sequence substantially identical to nucleotides +105 to +127 of the KDR/flk-1 promoter, i.e., 5' GGATATCCTCTCCTACCGGCAC 3' (SEQ ID

- 4 -

NO:4), or a combination thereof. Preferably, the 5' to 3' orientation of sequences is SEQ ID NO:1; SEQ ID NO:2 or SEQ ID NO:3; and SEQ ID NO:4. However, any orientation of these sequences which promotes endothelial cell-specific transcription is within the invention. The DNA may include a nonspecific sequence between any two of the defined sequences, and/or at either or both ends. Preferably, this nonspecific (i.e., sequence other than SEQ ID NO:1-4 will constitute no more than 80% of the entire promoter sequence. Most preferably, it is substantially identical to the sequence shown in Table 1 (SEQ ID NO:5) or Table 2 (SEQ ID NO:6).

A "substantially pure DNA," as used herein, refers to a DNA which has been purified from the sequences which flank it in a naturally occurring state, i.e., a DNA fragment which has been removed from the sequences which are normally adjacent to the fragment, e.g., the sequences adjacent to the fragment in the genome in which it naturally occurs.

A substantially pure DNA containing a sequence substantially identical to nucleotides -225 to +268 of the KDR/flk-1 promoter (SEQ ID NO:5; Table 1) or nucleotides -225 to +127 of the KDR/flk-1 promoter (SEQ ID NO:6; Table 2) and which regulates endothelial cell-specific transcription of a polypeptide-encoding sequence or antisense template to which it is operably linked is also within the invention.

TABLE 1: -225 to +268

TTGTTGCTCTGGGATGTTCTCTCCTGGGCGACTTGGGGCCCAGCGCAGTCCAGTTGT
GTGGGGAAATGGGGAGATGTAAATGGGCTTGGGGAGCTGGAGATCCCCGCCGGGTAC
CCGGGTGAGGGGCGGGGCTGGCCGCACGGGAGAGCCCCTCCTCCGCCCCGGCCCCGC
CCCGCATGGCCCCGCCTCCGCGCTCTAGAGTTTCGGCTCCAGCTCCCACCCTGCACT
GAGTCCCGGGACCCCGGGAGAGCGGTCAAGTGTGTGGTTCGCTGCGTTTCTCTGCCTG
CGCCGGGCATCACTTGCAGCGCCGCAGAAAGTCCGTCTGGCAGCCTGGATATCCTCTC
CTACCGGCACCCGCAGACGCCCTGCAGCCGCGGTTCGGCGCCCGGGCTCCCTAGCC
CTGTGCGCTCAACTGTCCTGCGCTGCGGGGTGCCGCGAGTTCCACCTCCGCGCCTCC
TTCTCTAGACAGGCGCTGGGAGAAAGAACCGGCTCCC (SEQ ID NO:5)

- 5 -

TABLE 2: -225 to +127

TTGTTGCTCTGGGATGTTCTCTCCTGGGCGACTTGGGGCCCAGCGCAGTCCAGTTGT
GTGGGGAAATGGGGAGATGTAAATGGGCTTGGGGAGCTGGAGATCCCCGCCGGGTAC
CCGGGTGAGGGGCGGGGCTGGCCGCACGGGAGAGCCCCCTCCTCCGCCCCGGCCCCGC
5 CCCGCATGGCCCCGCCTCCGCGCTCTAGAGTTTCGGCTCCAGCTCCCACCCTGCACT
GAGTCCCGGGACCCCGGGAGAGCGGTCAAGTGTGTGGTCGCTGCGTTTCCTCTGCCTG
CGCCGGGCATCACTTGCGCGCCGCGAGAAAGTCCGTCTGGCAGCCTGGATATCCTCTC
CTACCGGCAC (SEQ ID NO:6)

The DNA of the invention may be operably linked
10 to, and functions to regulate endothelial cell-specific
transcription of, a sequence encoding a polypeptide that
is not KDR/flk-1. Examples of such polypeptides include
tissue plasminogen activator (tPA), p21 cell cycle
inhibitor, and nitric oxide synthase. By "operably
15 linked" is meant able to promote transcription of an mRNA
corresponding to a polypeptide-encoding or antisense
template located downstream on the same DNA strand.

The invention also includes a vector containing
the DNA of the invention, a method of directing
20 endothelial cell-specific expression of a polypeptide by
introducing the vector into an endothelial cell, and an
endothelial cell containing the vector.

The vector of the invention can be used for gene
therapy, such as a method of inhibiting arteriosclerosis
25 in an animal involving contacting an artery of the animal
with the vector of the invention which directs the
production of a polypeptide capable of reducing or
preventing the development of arteriosclerosis, e.g., a
polypeptide which reduces proliferation of smooth muscle
30 cells, e.g., interferon- γ or atrial natriuretic
polypeptide.

The invention also includes compositions and
methods of carrying out antisense therapy. For example,
the invention includes a substantially pure DNA with a
35 sequence substantially identical to SEQ ID NO:1 which
regulates endothelial cell-specific transcription of an
antisense template to which it is operably linked, e.g.,

- 6 -

an antisense template the transcription product of which prevents translation of mRNA into an endothelial cell polypeptide. By the term "antisense template" is meant a DNA which is transcribed into an RNA which hybridizes to mRNA. Preferably, the endothelial cell polypeptide is KDR/flk-1. For example, the antisense RNA transcript which binds to and thereby prevents or reduces translation of an mRNA encoding KDR/flk-1, a protein involved in angiogenesis, can be used to treat cancer by contacting a tumor site in an animal with the DNA of the invention to reduce or prevent angiogenesis at the tumor site.

Translation of other endothelial cell polypeptides may also be reduced or prevented in this manner. For example, translation of cell cycle proteins, coagulation factors, e.g., von Willebrand factor, and endothelial cell adhesion factors, e.g., intercellular adhesion molecule-1 (ICAM-1) or vascular cell adhesion molecule-1 (VCAM-1) may be reduced or prevented.

The invention also features a method of measuring the ability of a candidate compound to modulate TNF- α downregulation VEGF receptor (e.g., KDR/flk-1 or flt1) gene expression. In this method, a cell containing the promoter of a VEGF receptor gene operably linked to a reporter gene is cultured in the presence of TNF- α and the candidate compound. The level of expression of the reporter gene is then determined as a measure of the ability of the candidate compound to modulate TNF- α downregulation of VEGF receptor gene expression.

Another method included in the invention involves measuring the ability of a candidate compound to modulate TNF- α inhibition of VEGF-induced endothelial cell proliferation. In this method, an endothelial cell is cultured in the presence of TNF- α , VEGF, and the candidate compound. The level of endothelial cell growth

- 7 -

is determined (e.g., by measurement of uptake of [methyl-³H]thymidine) as a measure of the ability of the candidate compound to modulate TNF- α inhibition of VEGF-induced endothelial cell proliferation.

5 The invention also features a method of inhibiting angiogenesis in a patient involving administering to the patient a non-TNF- α compound which activates the TNF- α pathway of downregulating VEGF receptor (e.g., KDR/flk-1 or flt1) gene expression in an endothelial cell.

10 An additional method of the invention for inhibiting angiogenesis in a patient involves administering to the patient a polypeptide which inhibits VEGF receptor (e.g., KDR/flk-1 or flt1) gene expression in an endothelial cell by binding to the TNF- α -responsive
15 element in the promoter of the VEGF receptor gene.

 The invention also features a method of enhancing angiogenesis in a patient involving administering to the patient a non-TNF- α compound which inhibits the TNF- α pathway of downregulating VEGF receptor (e.g., KDR/flk-1
20 or flt1) gene in an endothelial cell.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, from the drawings, and from the claims.

25 Detailed Description

 The drawings are first described.

Drawings

 Fig. 1A is a diagram of the human KDR/flk-1 promoter. Restriction enzyme sites are indicated above
30 the nucleotide sequence, and nucleotide sequences -780 to +487 (SEQ ID NO:7) are numbered on the left of the nucleotide sequence. The transcription start site is indicated by a curved arrow. Potential cis-acting elements are underlined. The PstI sites which were used

- 8 -

to generate the riboprobe are double underlined, and the sequence corresponding to the oligonucleotide which was used for primer extension is underlined with an arrow.

Fig. 1B is a diagram of the murine KDR/flk-1 promoter. Restriction enzyme sites are indicated above the nucleotide sequence. Nucleotide sequences -295 to +205 (SEQ ID NO:8) are numbered and potential cis-acting elements are indicated as in Fig. 1A. An asterisk indicates the 5' end of the cDNA.

Fig. 2A is a photograph of an electrophoretic gel showing the results of a primer extension analysis of the KDR/flk-1 transcription start site. The oligonucleotide underlined with an arrow in Fig. 1A was hybridized to 20 μ g of total RNA from human umbilical vein endothelial cells (HUVEC) and HeLa cells or 3 μ g of polyA⁺ HUVEC RNA and yeast tRNA. Extension products were analyzed on an 8% polyacrylamide gel (lanes 1-4: Yeast tRNA; HeLa total RNA; HUVEC total RNA; and HUVEC polyA⁺ RNA). A Sanger sequencing reaction primed on a plasmid DNA template (with the same oligonucleotide primer) was run next to the primer extension analyses (lanes 5-8: G; A; T; C).

Fig. 2B is a diagram showing the strategy for mapping the transcription start site of the KDR/flk-1 gene by ribonuclease protection.

Fig. 2C is a photograph of an electrophoretic gel showing a ribonuclease protection analysis of the KDR/flk-1 transcription start site. Total RNA from HUVEC and HeLa cells or polyA⁺ HUVEC RNA and yeast tRNA were incubated with a 559-bp ³²P-labeled riboprobe spanning the immediate 5' region of the human KDR/flk-1 gene. The annealing products were digested with RNase. Protected fragments were analyzed on a 4% polyacrylamide gel. The size markers (bp) were prepared by radiolabeling ϕ X174 RF DNA digested with HaeIII. Fig. 3A is a diagram showing the location of 5' deletion sites in the

- 9 -

KDR/flk-1 promoter. Location of deletion sites is shown in relation to consensus sequences for known nuclear proteins.

Fig. 3B is a bar graph showing the results of a functional analysis of the human KDR/flk-1 promoter by transfection of luciferase reporter constructs containing serial 5' deletions into bovine aortic endothelial cells (BAEC). All constructs were cotransfected with pSV β gal to correct for transfection efficiency, and luciferase activity was expressed as a percentage of pGL2 Control (mean \pm SEM). Fig. 4A is a diagram showing the location of 3' deletion sites in the KDR/flk-1 promoter. Location of deletion sites is shown in relation to consensus sequences for known nuclear proteins.

Fig. 4B is a bar graph showing the results of a functional analysis of 3' deletions on KDR/flk-1 promoter activity in BAEC. Luciferase activity is represented as a percentage of pGL2 control.

Fig. 5 is a bar graph showing the effect of a GATA site mutation on KDR/flk-1 promoter activity. Mutation of the GATA site at position +107 does not decrease the ability of the KDR/flk-1 promoter to direct transcription. When transfected into BAEC, the plasmid pGL2-225+268 directed luciferase expression comparable to that directed by pGL2 Control, which contains the SV40 promoter and enhancer. When three bp of the GATA motif at +107 were mutated to create pGL2 GATA-MUT, there was no significant difference in promoter activity.

Fig. 6A is a photograph of a Northern blot analysis showing that KDR/flk-1 RNA expression is restricted to endothelial cells in culture. RNA was extracted from cells in culture and analyzed by Northern blotting using a human KDR/flk-1 cDNA probe. The following cell types were tested: HUVEC (human umbilical vein endothelial cells), HASMC (human aortic smooth

- 10 -

muscle cells), HISMC (human intestinal smooth muscle cells), fibroblasts (human cultured fibroblasts), RD (human embryonal rhabdomyosarcoma cells) HeLa (human epidermoid carcinoma cells), HepG2 (human hepatoma
5 cells), MCF7 (human breast adenocarcinoma cells), and U937 (human histiocytic lymphoma cells).

Fig. 6B is a photograph of the same agarose gel shown in Fig. 6A which was stained with ethidium bromide (to visualize ribosomal RNA) to show the amount of RNA
10 loaded in each lane.

Fig. 7 is a bar graph showing the results of a luciferase assay. High-level activity of the KDR/flk-1 promoter was found to be specific to endothelial cells. The luciferase reporter construct pGL2-4kb+296 was
15 transfected into cells in culture, and transfection efficiency was assessed by monitoring cotransfection with pSV β gal. Results are corrected for transfection efficiency and expressed as a percentage of pGL2 Control activity for each cell type. The following cell types
20 were tested: BAEC, bovine aortic endothelial cells; JEG-3, human choriocarcinoma cells; Saos-2, human osteosarcoma cells; A7r5, rat fetal smooth muscle cells; 3T3, mouse fibroblasts; and HeLa, human epidermoid carcinoma cells.

25 Fig. 8 is a bar graph showing the effect of TNF- α on VEGF-induced proliferation of HUVEC, as measured by uptake of methyl-[3 H]thymidine.

Fig. 9A is a photograph of a Northern blot analysis of a time course of TNF- α -induced downregulation
30 of KDR/flk-1 mRNA expression in HUVEC. From left to right, the time points are: 0, 1, 2, 3, 6, 12, and 24 hours, as indicated in Fig. 9B.

Fig. 9B is a bar graph of the results of the time course of TNF- α -induced downregulation of KDR/flk-1 mRNA
35 expression shown in the photograph of Fig. 9A.

- 11 -

Fig. 10A is a photograph of a Northern blot analysis of a dose-response experiment of TNF- α -induced downregulation of KDR/flk-1 mRNA expression in HUVEC. From left to right, 1. 0.1, 1, 10, 50, and 100 ng/ml TNF- α were used, as indicated in Fig. 10B.

Fig. 10B is a bar graph of the results of the dose-response experiment of TNF- α -induced downregulation of KDR/flk-1 mRNA expression in HUVEC shown in the photograph of Fig. 10A.

Fig. 11 is a graph showing the effect of Actinomycin D (ACD) on the levels of KDR/flk-1 RNA in HUVEC.

Fig. 12. is a photograph of immunoprecipitation analysis of KDR/flk-1 protein in HUVEC treated with TNF- α for 0, 12, and 24 hours.

Isolation and Characterization of KDR/flk-1 Genomic Clones

Screening of Human and Mouse Genomic Libraries

A 567-bp human KDR/flk-1 cDNA fragment was generated from HUVEC total RNA by reverse-transcriptase polymerase chain reaction (RT-PCR). This fragment was radiolabeled with [α - 32 P]dCTP and used to screen a phage library of human placenta genomic DNA in the vector λ FixII (Stratagene, La Jolla, CA). Likewise, a 451-bp mouse KDR/flk-1 cDNA was generated by RT-PCR from mouse lung total RNA and used to screen a phage library of mouse placenta genomic DNA in the vector λ DashII (Stratagene). Hybridizing clones were isolated and purified from each library, and phage DNA was prepared according to standard procedures.

Cell Culture and mRNA Isolation

BAEC were isolated and cultured in Dulbecco's modified Eagle's medium (JRH Biosciences, Lenexa, KS) supplemented with 10% fetal calf serum (HyClone, Logan,

- 12 -

UT), 600 µg of glutamine/ml, 100 units of penicillin/ml, and 100 µg of streptomycin/ml. Cells were passaged every 3-5 days and cells from passages 4-8 were used for transfection experiments. Saos-2 human osteosarcoma cells (ATCC HTB-85), HeLa human epidermoid carcinoma cells (ATCC CRL-7923), HepG2 human hepatoma cells (ATCC HB-8065), human fibroblasts (ATCC CRL-1634), U937 human histiocytic lymphoma cells (ATCC CRL-7939), RD human embryonal rhabdomyosarcoma cells (ATCC CCL-136), MCF7 human breast adenocarcinoma cells (ATCC HTB-22), JEG-3 human choriocarcinoma cells (ATCC HTB-36), A7r5 fetal rat aortic smooth muscle cells (ATCC CRL-1444), and NIH 3T3 mouse fibroblasts (ATCC CRL-1658) were obtained from the American Type Culture Collection. Primary-culture HUVEC were obtained from Clonetics Corp. (San Diego, CA) and were grown in EGM medium containing 2% fetal calf serum (Clonetics). Primary-culture human aortic and intestinal smooth muscle cells were also obtained from Clonetics Corp. All cells were cultured in conditions identical to those for BAEC, with the exception that medium used for smooth muscle cells was supplemented with 25 mM HEPES (Sigma, St. Louis, MO) and that HUVEC were cultured in EGM medium containing 2% fetal calf serum. Primary-culture cells were passaged every 4-6 days, and cells from passages 3-5 were analyzed. Total RNA from cells in culture was prepared by guanidinium isothiocyanate extraction and centrifugation through cesium chloride.

DNA Sequencing

Restriction fragments derived from the human and mouse KDR/flk-1 genomic phage clones were subcloned using standard techniques into pSP72 (Promega, Madison, WI) or pBluescript II SK (Stratagene) and sequenced from alkaline- denatured double-stranded plasmid templates by the dideoxy chain termination method with SEQUENASE® 2.0

- 13 -

DNA polymerase (United States Biochemical, Cleveland, OH). DNA was sequenced from both directions at least twice, and both dGTP and dITP sequencing protocols were used to resolve compression artifacts in the highly GC-rich 5' flanking region of the human and mouse KDR/flk-1 genes. Sequence analysis was performed with the GCG software package (Genetics Computer Group, Madison, WI).

Primer Extension Analysis

Primer extension analysis was performed according to known methods, e.g., the method of Fen et al., 1993, Biochemistry 32:7932-7938. A synthetic oligonucleotide primer (5' CTGTCTAGAGAAGGAGGCGCGGAGGTGGA ACT 3'; SEQ ID NO:9) complementary to the 5' end of the human KDR/flk-1 cDNA (Fig. 1A) was end-labeled with [γ -³²P]ATP and hybridized to 20 μ g of each RNA sample, which was then subjected to reverse transcription. Extension products were analyzed by electrophoresis on an 8% denaturing polyacrylamide gel.

Ribonuclease Protection Assay

A 559-bp PstI-PstI fragment of the human KDR/flk-1 gene (Fig. 2B) was cloned in pSP72 as the template for in vitro transcription of an α -³²P-labeled antisense RNA with T7 RNA polymerase (Boehringer Mannheim, Indianapolis, IN). Gel-purified riboprobe (5×10^5 cpm) was hybridized with 20 μ g of total RNA or 3 μ g of polyA RNA plus 17 μ g of yeast tRNA at 55°C for 16 hours in an annealing buffer containing 20 mM Tris-HCl, pH 7.40, 400 mM NaCl, 1 mM EDTA, and 0.1% sodium dodecyl sulfate in 75% formamide. After the RNA had been annealed, the unhybridized RNA was digested for 45 minutes at room temperature with 200 U RNase T1 (Boehringer Mannheim) and 0.3 U RNase A (Boehringer Mannheim) in a buffer containing 10 mM Tris-HCl, pH 7.50, 300 mM NaCl, 5 mM EDTA. The digestion products were then treated with proteinase K, extracted

- 14 -

with phenol:chloroform, and analyzed by electrophoresis on a 4% denaturing polyacrylamide gel.

Northern Analysis

Total RNA (10 µg) from cells in culture was
5 fractionated on a 1.3% formaldehyde-agarose gel and transferred to a nitrocellulose filter. The human KDR/flk-1 cDNA probe was labeled with ³²P by random priming, the labeled probe was then used to hybridize the filter. The filter was then autoradiographed for 16
10 hours on Kodak XAR film at -80°C.

Plasmids

Plasmids pGL2 Basic and pGL2 Control contained the firefly luciferase gene (Promega). pGL2 Basic had no promoter, whereas pGL2 Control was driven by the SV40
15 promoter and enhancer. The plasmid pSVβGAL (Promega) contained the β-galactosidase gene driven by the SV40 promoter and enhancer.

Reporter constructs containing fragments of the human KDR/flk-1 5' flanking region were inserted into
20 pGL2 Basic and named according to the length of the fragment (from the transcription start site) in the 5' and 3' directions. For example, plasmid pGL2-4kb+296 contained a human KDR/flk-1 promoter fragment extending from approximately -4 kb 5' of the transcription start
25 site to position +296 inserted into pGL2 Basic. Plasmids pGL2-4kb+296 and pGL2-900+296 were created by restriction digestion of purified phage DNA by using 5' BamHI and PvuII sites, respectively, and the 3' XhoI site at position +296. Plasmids pGL2-716+268, pGL2-570+268,
30 pGL2-323+268, pGL2-225+268, pGL2-164+268, pGL2-37+268, pGL2-225+127, pGL2-225+105, pGL2-225+56, and pGL2-225+5 were created from promoter fragments generated by PCR of human KDR/flk-1 phage DNA. Plasmids pGL2-116+268, pGL2-95+268, pGL2-77+268, pGL2-60+268, and pGL2-12+268 were
35 created by digesting the promoter fragment contained in

- 15 -

plasmid pGL2-164+268 from the 5' end with exonuclease III (Pharmacia Biotech, Piscataway, NJ). Plasmid pGL2 GATA-MUT was identical to pGL2-225+268 except that bp +108 to +110 were mutated in the plasmid pGL2 GATA-MUT.

- 5 All constructs were sequenced from the 5' and 3' ends to confirm orientation and sequence.

Mutagenesis

- Site-directed mutagenesis of the atypical GATA sequence located in the first exon of the human KDR/flk-1 5' flanking region was performed by PCR using to the method of Higushi et al., 1988, Nucleic Acids Res. 16:7351-7367. A DNA fragment containing human KDR/flk-1 bp -225 to +268 was used as a template. The sequence TGGATATC was mutated to TGGTCGTC by using one set of 15 mismatched primers, 5' TCTGGCAGCCTGGTCGTCCTCTCCTA 3' (SEQ ID NO:10) and 5'TAGGAGAGGACGACCAGGCTGCCAGA 3' (SEQ ID NO:11), and one set of primers flanking both ends of the template, 5' TGCCTCGAGTTGTTGCTCTGGGATGTT 3' (SEQ ID NO:12) and 5' TGTAAGCTTGGGAGCCGGTTCTTTCTC 3' (SEQ ID 20 NO:13). The sequence of the mutated PCR fragment was confirmed by the dideoxy chain termination method.

Transfections

- All cell types were transfected by the calcium phosphate method known in the art with the exception of 25 A7r5 cells, which were transfected with DOTAP (Boehringer Mannheim) as instructed by the manufacturer. In all cases, 20 µg of the appropriate reporter construct was transfected along with 2.5 µg of pSVβgal to correct for variability in transfection efficiency. Cell extracts 30 were prepared 48 hours after transfection by a detergent lysis method (Promega). Luciferase activity was measured in duplicate for all samples with an EG&G Autolumat 953 luminometer (Gaithersburg, MD) and the Promega Luciferase Assay system. β-Galactosidase activity was assayed using

- 16 -

known methods, e.g., Lee et al., 1990, J. Biol. Chem. 265:10446-10450.

The ratio of luciferase activity to β -galactosidase activity in each sample served as a measure of the normalized luciferase activity. The normalized luciferase activity was divided by the activity of pGL2 Control and expressed as relative luciferase activity. Each construct was transfected at least six times, and data for each construct are presented as the mean \pm SEM. Relative luciferase activity among constructs was compared by a factorial analysis of variance followed by Fisher's least significant difference test. Statistical significance was accepted at $p < 0.05$.

15 Isolation and Characterization of Human and Murine KDR/flk-1 Genomic Clones

Initial screening of a human placental phage library with a human KDR/flk-1 cDNA probe yielded a positive clone that was examined by restriction enzyme DNA mapping, subcloning, and sequencing. The 780-bp sequence of the promoter and first exon is shown in Fig. 1A. Likewise, a murine KDR/flk-1 cDNA probe was used to screen a murine placental phage library, and one clone was identified and characterized. The sequence of the mouse KDR/flk-1 promoter is shown in Fig. 1B.

25 Identification of the Transcription Start Site of Human KDR/flk-1

To identify the transcription start site of the human KDR/flk-1 gene, primer extension was performed with a complementary oligonucleotide probe corresponding to bp +212 to +243 (underlined with arrow, Fig. 1A). Primer extension was performed on total RNA from HUVEC and HeLa cells and on polyA RNA from HUVEC. Gene transcription was found to be initiated only in endothelial cells (Fig. 2A). A single transcription start site, corresponding to

- 17 -

a nucleotide located 303 bp 5' of the site of translation initiation, i.e., the methionine initiation codon, was identified. This nucleotide was designated +1. The transcription start site is highlighted in bold in the
5 sequence, CCCTGCACTGA (SEQ ID NO:14) (see Figs. 1A and 2A). The 5'CA3' nucleotide pair at this position is the most common site for transcription initiation.

To confirm the results of the primer extension studies, a ribonuclease protection analysis was performed
10 using an antisense riboprobe generated from a 559-bp genomic PstI-PstI fragment extending 5' from position +146 (Fig. 2B; the PstI sites are double underlined in Fig. 1A). Incubation of this probe with HUVEC polyA RNA and HUVEC total RNA, but not with total RNA from HeLa
15 cells, resulted in protection of a single fragment corresponding in length to the distance between the 3' PstI site and the transcription start site identified by primer extension (Fig. 2C). Despite the absence of a TATA consensus sequence, transcription of the human
20 KDR/flk-1 gene was found to begin from a single site located 303 bp 5' of the translation initiation codon (Fig. 1A, curved arrow).

Identification of Cis-Acting Sequences

The 5' flanking sequence of the human KDR/flk-1
25 gene contains regions rich in G and C residues and lacks TATA and CCAAT boxes near the transcription start site (Fig. 1A). Comparison of this 5' flanking sequence with sequences in the Transcription Factors Database revealed a series of five Sp1 sites located between human
30 KDR/flk-1 nucleotides -124 and -39. There are two AP-2 consensus sites at positions -95 and -68 and two inverted NFkB binding elements at -130 and -83 interspersed among the Sp1 sites. Two atypical GATA consensus sequences (both GGATAT) are present in the KDR/flk-1 promoter, one
35 at position -759 and the other at position +107 within

- 18 -

the untranslated portion of the first exon. In addition, multiple CANNTG elements are located in the promoter at positions -591, -175, +71, and +184; CANNTG elements can be bound by E-box binding proteins. The sequence
5 AAACCAAA, which is conserved among genes expressed preferentially in keratinocytes, is present at human KDR/flk-1 position -508.

The human and mouse KDR/flk-1 promoters were compared to identify conserved consensus sequences for
10 nuclear proteins (Fig. 1B). Elements conserved between the two species include two Sp1 sites located at positions -244 and -124 relative to the 5' end of the reported mouse cDNA sequence, two AP-2 sites at positions -168 and -148, a noninverted NF κ B site at position -153,
15 and the keratinocyte element AAACCAAA at position -195. An atypical GATA element (GGATAA) is located in the untranslated portion of the first exon of the mouse promoter at position +18; an atypical GATA element (GGATAT) is located similarly in the human promoter.
20 Also, a CANNTG sequence is present 12 bp 5' of the G- and C-rich sequences of the promoter at mouse KDR/flk-1 position -257, a location analogous to that of the CANNTG element at position -175 of the human promoter. Conservation of these elements across species suggests
25 that these regulatory elements have functional significance.

Deletion Analysis of the Human KDR/flk-1 Promoter

To identify DNA elements important for basal expression of KDR/flk-1 in endothelial cells, a series of
30 luciferase reporter plasmids containing serial 5' deletions through the promoter region was constructed (Figs. 3A and 3B). These plasmid constructs in pGL2 Basic were cotransfected into BAEC with pSV β gal (to correct for differences in transfection efficiency) and
35 the luciferase activity was normalized to that of the

- 19 -

pGL2 Control vector driven by the SV40 promoter/enhancer. The activity of the longest human KDR/flk-1 genomic fragment, spanning bp -4kb to +296, was similar to that of the powerful SV40 promoter/enhancer and consistent with the high level of KDR/flk-1 mRNA expression in endothelial cells. Similar levels of activity were produced in constructs containing as much as 15.5 kb of 5' flanking sequence. Serial 5' deletions from bp -4kb to -225 caused no significant change in promoter activity, implying that elements in this region are not important for basal activity of the KDR/flk-1 promoter. Deletion of sequences between bp -225 and -164 significantly reduced KDR/flk-1 promoter activity to 63% of the activity of the full promoter fragment ($p < 0.05$). These data suggest the presence of positive regulatory elements in this region. Deletion of bp from -95 to -77, a sequence that contains one AP-2 site and one NF κ B site, resulted in a further significant decrease in activity to 20% that of pGL2-4kb+296 ($p < 0.05$). Further deletion of bp from -77 to -60, an area containing an overlapping AP-2/Sp1 site, significantly reduced KDR/flk-1 promoter activity to less than 5% that of pGL2-4kb+296 ($p < 0.05$). Thus, 5' deletion analysis revealed that many positive regulatory elements in the KDR/flk-1 promoter are necessary for high-level expression of the gene.

The deletion analyses described above indicate that three sequences within the 5' flanking region of the KDR/flk-1 gene contain elements important for expression in endothelial cells. Potential binding sites for Sp1, AP-2, NF κ B, and E-box proteins located within these three positive regulatory elements in the human KDR/flk-1 gene are also present in the mouse 5' flanking sequence, thus suggesting that they are functional binding domains. AP-2 is a developmentally regulated trans-acting factor (Mitchell et al., 1991, Genes & Dev. 5:105-119) without a

- 20 -

demonstrated role in endothelial cell gene regulation. NF κ B is thought to trans-activate the inducible expression of vascular cell adhesion molecule-1 and tissue factor in endothelial cells (Iademarco, 1992, J. Biol. Chem. 267:16323-16329; Moll et al., 1995, J. Biol. Chem. 270:3849-3857) and is known to be a mediator of tissue-specific gene regulation (Lenardo et al., 1989, Cell 58:227-229). Nuclear proteins that bind the E-box motif include the basic helix-loop-helix family of trans-acting factors. E-box binding proteins have not been clearly associated with endothelial cell gene expression, although members of this family are critical for proper maturation of many cell types, including skeletal muscle and B lymphocytes (Buskin et al., 1989, Mol. Cell. Bio. 9:2627-2640; Murre et al., 1989, Cell 58:537-544).

To determine whether sequences in the first exon of human KDR/flk-1 are important for basal expression, a series of 3' deletion constructs from the vector pGL2-225+268, which is the smallest construct that possessed full promoter activity, was made (Figs. 4A and 4B). Deletion of a fragment spanning bp +105 to +127 (SEQ ID NO:4) caused a five-fold reduction in promoter activity ($p < 0.05$), indicating the presence of a positive regulatory element in this region.

The functional importance of the atypical GATA site located between bp +105 and +127 of human KDR/flk-1 was also examined. Three bp of the GATA motif in the fragment -225 to +268 were mutated to GTCG by PCR to create the mutant, pGL2 GATA-MUT. Mutation of these bp in the GATA motif eliminates GATA-2 binding activity in the endothelin-1 gene promoter. In contrast, there was no significant decrease in promoter activity in BAEC with the pGL2 GATA-MUT construct containing the mutated

- 21 -

atypical GATA sequence compared to the native pGL2-225+268 promoter construct, ($p > 0.05$; Fig. 5).

Four zinc finger-containing transcription factors in the GATA protein family bind to the consensus sequence (A/T)GATA(A/G) and regulate cell type-specific gene expression in many cell lineages (Orkin, 1992, Blood 80:575-581); among these, GATA-2 has been most closely linked to endothelial cell gene expression. GATA-2 functions as an enhancer of endothelin-1 gene expression and acts to restrict expression of von Willebrand factor to endothelial cells. Human KDR/flk-1 5' flanking region was found to have two potential GATA-binding sequences, at positions -759 and +107. Loss of the element located at position -759 had no effect on expression of KDR/flk-1 in endothelial cells. The potential GATA element at position +107 is located in a region of the first exon which has now been identified as a powerful positive regulatory element (SEQ ID NO:4). Although this GATA sequence (GGATAT) differs from the GATA-binding sequences of endothelin-1 and von Willebrand factor and from the consensus GATA sequence (A/T)GATA(A/G), the data suggests that it is the functional motif in the region between +105 and +127 because the functional GATA site in the von Willebrand factor gene is located similarly in the first exon, and because a similar GATA element is found in the first exon of the mouse KDR/flk-1 gene. Mutation of three bp in this element (GATA to GTCG), which had been observed to prevent trans-activation of the GATA cis-acting element in the endothelin-1 promoter, was found to have no significant effect on KDR/flk-1-promoter activity (Fig. 5). Thus, the deletion analyses and mutagenesis studies do not support a functional role for the two GATA sequences in the human promoter in its high-level activity in endothelial cells. These observations suggest that transcription factors other

- 22 -

than GATA proteins are necessary for expression of the human KDR/flk-1 gene.

High-Level Expression Induced by the KDR/flk-1 Promoter Is Specific to Endothelial Cells

5 Although KDR/flk-1 expression is restricted to endothelial cells *in vivo*, it does not necessarily follow that its expression would be limited to endothelial cells in culture. To determine whether a tissue culture system is suitable for studying cell-type specific regulation of
10 the KDR/flk-1 gene, Northern analysis of RNA extracted from various cells in culture was performed. KDR/flk-1 message was detected in HUVEC but not in primary-culture cells (human aortic and intestinal smooth muscle cells and fibroblasts) or human cell lines (RD, HeLa, HepG2,
15 MCF7, and U937) (see Figs. 6A and 6B). Similarly, KDR/flk-1 message was not detected by RT-PCR in HeLa, A7r5, or 3T3 cells. Thus, expression of KDR/flk-1 message in tissue culture appears to be restricted to endothelial cells, as it is *in vivo*.

20 To determine whether 5' flanking sequences of the KDR/flk-1 gene can confer endothelial cell-specific expression in cultured cells, pGL2-4kb+296, which contains over 4 kb of the human KDR/flk-1 5' flanking sequence and includes most of the untranslated portion of
25 the first exon, was transfected into a variety of cell types in culture (Fig. 7). Reporter gene expression driven by the pGL2-4kb+296 promoter fragment was similar to that driven by the potent SV40 promoter/enhancer. In JEG-3, Saos-2, A7r5, 3T3, and HeLa cells, however,
30 expression driven by the pGL2-4kb+296 promoter was markedly lower, demonstrating that induction of high-level expression by these promoter sequences is specific to endothelial cells. A similar expression pattern was observed using a reporter plasmid containing
35 15.5 kb of KDR/flk-1 5' flanking sequence.

- 23 -

These data indicate that the activity of the KDR/flk-1 promoter in endothelial cells is similar to that of the potent SV40 promoter/enhancer and that this high-level activity is specific to endothelial cells; activity in other cell types is markedly diminished. Low, but detectable, promoter activity was observed in transient transfection assays of cell types that do not express the KDR/flk-1 gene in vivo; it is possible that other silencer elements outside of the 15.5 kb 5' flanking region are necessary to block promoter activity completely in non-endothelial cells. Alternatively, the context of the promoter in relation to normal chromatin structure may be essential for precise regulation of the gene. The results described above suggest that tissue-specific regulation of KDR/flk-1 involves a complex interaction between known, widely distributed nuclear factors and other, undefined elements.

TNF- α Downregulates KDR/flk-1 and flt1 Expression

Cell Culture and mRNA Isolation

Primary-culture HUVEC and HAEC were obtained from Clonetics Corp. (San Diego, CA) and were grown in M199 medium supplemented with 20% fetal calf serum (Hyclone, Logan, UT), 30 mg endothelial cell growth substance (ECGS, Collaborative Biomedical, Bedford, MA), 25 mg heparin, 600 μ g of glutamine/ml, 100 units of penicillin/ml, and 100 μ g of streptomycin/ml, in gelatin-coated tissue culture plates. Bovine aortic endothelial cells (BAEC) were isolated and cultured in Dulbecco's modified Eagle's medium (JRH Biosciences, Lenexa, KS) supplemented with 10% fetal calf serum. Primary-culture cells were passaged every 4-6 days and experiments were performed on cells three to six passages from primary culture. After the cells had grown to confluence, they were placed in serum-deprived medium (M199 medium

- 24 -

supplemented with 5% fetal calf serum without ECGS). Recombinant human TNF- α (Genzyme, Cambridge, MA) was aliquoted and stored at -80°C until use. Total RNA from cells in culture was prepared by guanidinium

5 isothiocyanate extraction and centrifugation through cesium chloride (Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York).

10 Northern Analysis

RNA blots were hybridized as described (Li et al., 1995, J. Biol. Chem. 270:308-312). Total RNA (10 μ g) from cells in culture was fractionated on a 1.3% formaldehyde-agarose gel and transferred to

15 nitrocellulose filters. cDNA probes were labeled with 32 P by random priming and used to hybridize to the filters. Filters were then washed and subject to autoradiography for 4-8 hours on Kodak XAR film at -80°C. Filters were stripped of radioactive probe in a 50% formamide solution
20 at 80°C and rehybridized with an end-labeled 18S ribosomal RNA oligonucleotide to correct for loading. Filters were scanned and radioactivity was measured on a PhosphorImager running the ImageQuant software (Molecular Dynamics, Sunnyvale, CA). To correct for differences in
25 RNA loading, the signal intensity for each RNA sample hybridized to the cDNA probes was divided by that for each sample hybridized to the 18S ribosomal RNA probe.

Plasmids

A 567-bp human KDR/flk-1 cDNA fragment was
30 generated from human umbilical vein endothelial cell (HUVEC) total RNA by the reverse-transcriptase polymerase chain reaction (RT-PCR) (Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New
35 York), as previously described (Patterson et al., 1995,

- 25 -

J. Biol. Chem. 270:2311-23118). The human *flt1* cDNA clone was generously provided by Dr. Timothy Quinn (University of California, San Francisco).

Nuclear Run-on Analysis

5 Confluent HUVEC were treated with either vehicle (control) or TNF- α (1 ng/ml) for 18 hours. The cells were subsequently lysed, and the nuclei were isolated, as described in Perrella et al. (Perrella et al., 1994, J. Biol. Chem. 269:14595-14600). Nuclear suspension (200
10 μ l) was incubated with 0.5 mM each of CTP, ATP, and GTP, and with 20 μ Ci of 32 P-labeled UTP (3000 Ci/mmol, DuPont/NEN, Boston, MA). The samples were extracted with phenol/chloroform, precipitated, and resuspended at equal counts/minute/ml in hybridization buffer (15×10^6
15 counts/minute/ml). Denatured probes (1 μ g) dot-blotted onto nitrocellulose filters were hybridized with the samples at 40°C for 4 days in the presence of formamide. cDNAs for the KDR/*flk-1* and β -actin genes were used as probes. The filters were scanned and radioactivity was
20 measured on a PhosphorImager running ImageQuant software. The amount of sample hybridizing to the KDR/*flk-1* probe was divided by that hybridizing to the β -actin probe, and the corrected density was reported as the percentage change from the control.

25 Immunoprecipitation

HUVEC in confluent monolayers were serum-deprived for 24 hours and treated with TNF- α (1 ng/ml) or vehicle for the indicated times. The cells were incubated with 35 S-methionine (100 μ Ci/ml, DuPont/NEN) for two hours and
30 lysed in RIPA buffer at 4°C for ten minutes. After sedimentation of the insoluble fraction, the protein extract was pre-cleaned with Protein A sepharose (0.1 μ g/ μ l, Pharmacia Biotech, Piscataway, NJ) for one hour at 4°C followed by centrifugation and collection of
35 the supernatant. Protein concentrations in the whole

- 26 -

cell lysates were determined by a modified Lowry procedure (DC protein assay; Bio-Rad, Melville, NY) and were confirmed by SDS-polyacrylamide gel fractionation of samples followed by Coomassie Blue staining. Protein
5 samples (500 μ g) were diluted to 1 μ g/ μ l with immunoprecipitation buffer (50 mM Tris-Cl, pH 8.0, 150 mM NaCl, 0.1% SDS, 1 NP40, 0.5% sodium deoxycholate, 2 mM EDTA, 0.5 mM DTT, 0.02% sodium azide) plus 4 mg/ml BSA, and rocked gently at 4°C for one hour. Specific antibody
10 was added to a concentration of 50 μ g/ μ l and the sample was rocked at 4°C for 1.5 hours. Protein A sepharose (10 μ g) was added and rocking was continued for 1.5 hours. The antigen-antibody-Protein A sepharose conjugates were removed by centrifugation and washed four times with
15 immunoprecipitation buffer. The conjugates were denatured at 100°C for 5 minutes in Laemmli buffer and size fractionated on a 7% SDS-polyacrylamide gel, which was then vacuum-dried and subject to autoradiography. Autoradiograms were scanned with a Howtek Scanmaster 3+
20 (Hudson, NH) using Adobe Photoshop 3.0, and Scion Image 1.55 was used to quantitate the immunoprecipitated protein.

[³H]Thymidine Incorporation

HUVEC grown to near confluence in gelatin-coated
25 24-well tissue culture plates were serum-deprived and pretreated with vehicle or TNF- α (1 ng/ml) for 12 hours before addition of recombinant human VEGF (10 ng/ml, Collaborative) or vehicle. Cells were treated with VEGF for 24 hours and were labeled with methyl-[³H]thymidine
30 (DuPont/NEN) at 1 μ Ci/ml during the last three hours of VEGF treatment. After labeling, the cells were washed with phosphate-buffered saline, fixed in cold 10% trichloroacetic acid, and washed with 95% ethanol. Incorporated [³H]thymidine was extracted in 0.2 M NaOH
35 and measured in a liquid scintillation counter. Values

- 27 -

were expressed as the mean \pm SEM from 6 wells from two separate experiments.

Statistical analysis

When appropriate, data from image analyses and
5 [³H]thymidine incorporation were expressed as the mean \pm SEM. Statistical analysis of multiple treatment groups was performed using a factorial analysis of variance followed by Fisher's least significant difference test. Statistical significance was accepted at $p < 0.05$.

10 Effect of TNF- α on VEGF-induced Endothelial Cell Proliferation

TNF- α has previously been demonstrated to blunt the mitogenic action of acidic and basic fibroblast growth factors on bovine aortic endothelial cells in a
15 concentration-dependent manner (Frater-Schroder et al., 1987, Proc. Natl. Acad. Sci. USA 84:5277-5281). To determine whether TNF- α also blocks the proliferative effect of VEGF on human endothelial cells, [³H]thymidine incorporation was measured as a marker for DNA synthesis
20 after stimulating HUVEC with human recombinant VEGF. In serum-deprived HUVEC, pretreatment with TNF- α alone in concentrations similar to those used by Frater-Schroder et al. (Frater-Schroder et al., 1987, Proc. Natl. Acad. Sci. USA 84:5277-5281) decreased [³H]thymidine
25 incorporation only slightly in comparison to HUVEC pretreated with vehicle (Fig. 8). In comparison to control cells, VEGF treatment alone potently enhanced [³H]thymidine incorporation in HUVEC by 2.3-fold, as has been previously demonstrated (Connolly et al., 1989, J.
30 Clin. Invest. 84:1470-1478). However, pre-treatment of HUVEC with TNF- α totally abolished the effect of VEGF on DNA synthesis. These results demonstrate that TNF- α blocks the proliferative response of HUVEC to VEGF.

- 28 -

Downregulation of VEGF Receptor mRNA by TNF- α in HUVEC

The 5.7 kb KDR/flk-1 mRNA is constitutively expressed in HUVEC (Patterson et al., 1995, J. Biol. Chem. 270:2311-23118). The 7.0 kb flt1 mRNA is also
5 abundantly expressed by HUVEC in culture. Treatment of HUVEC with TNF- α (10 ng/ml) resulted in a decrease in the mRNA for both receptors (KDR/flk-1 and flt1) that was evident by 6 hours, and that reached 28% and 33% of 0-hour values,
10 respectively, for KDR/flk-1 and flt1 after 24 hours of treatment (Figs. 9A and 9B). That this effect was due to TNF- α alone, and not to serum deprivation, was demonstrated by including a control sample which was serum-deprived for 24 hours and treated with vehicle
15 alone; serum deprivation alone actually slightly induced both KDR/flk-1 and flt1 messages. To exclude the possibility that the downregulation of these two receptors was due to a generalized decrease in mRNA production induced by TNF- α , the same blots were
20 hybridized to a human heparin-binding epidermal growth factor-like factor (HB-EGF) probe. Under these conditions, TNF- α induced a biphasic increase in HB-EGF message, consistent with the results of previous experiments (Yoshizumi et al., 1992, J. Biol. Chem.
25 267(14):9467-9469). To demonstrate that the effect of TNF- α was not specific to endothelial cells of venous origin, identical experiments were performed with human aortic endothelial cells (HAEC). A similar potent decrease in the message for both receptors was noted in
30 HAEC. The message for KDR/flk-1 was also decreased by TNF- α in bovine aortic endothelial cells, demonstrating that the effect of TNF- α is not species-specific.

TNF- α also decreased the messages for KDR/flk-1 and flt1 in a dose-dependent fashion (Figs. 10A and 10B).
35 As little as 1 ng/ml TNF- α inhibited the mRNA for both

- 29 -

receptors to near maximal levels, with KDR/flk-1 being slightly more sensitive than flt1 to the effects of TNF- α in HUVEC. Thus, TNF- α specifically downregulates the mRNA for the VEGF receptors KDR/flk-1 and flt1 in a time and dose-dependent fashion in human endothelial cells.

TNF- α Decreased the Rate of Transcription, But Had No Effect on the Half-Life, of KDR/flk-1

To determine whether TNF- α affected the steady-state level of KDR/flk-1 mRNA by increasing its rate of degradation, KDR/flk-1 mRNA was measured in the presence of actinomycin D (ACD; 5 μ g/ml). The KDR/flk-1 mRNA half-life was 1.9 hours in the absence of TNF- α and increased slightly, to 2.6 hours, in the presence of TNF- α (Fig. 11). In similar experiments, the mRNA half-life of flt1 was found not to be decreased by TNF- α in HUVEC. Thus, the TNF- α -induced decrease in the level of KDR/flk-1 and flt1 mRNAs in HUVEC was not due to a decrease in the stability of the mRNA.

Nuclear run-on experiments were performed to determine the rate of KDR/flk-1 gene transcription in the presence or absence of TNF- α , and to compare it with the rate of transcription of the constitutively expressed β -actin gene. TNF- α decreased the rate of KDR/flk-1 gene transcription (measured in PhosphorImager units) to 40% of baseline, but had no effect on the transcription of β -actin. Thus, the TNF- α -induced decrease in KDR/flk-1 mRNA was due to a decrease in the rate of transcription of the gene in HUVEC and not to a change in the stability of the mRNA.

The Decrease in KDR/flk-1 mRNA by TNF- α is Protein Synthesis-Dependent

Whether the decrease in KDR/flk-1 mRNA required protein synthesis was examined using the protein synthesis inhibitor anisomycin. Concentrations of anisomycin used (50 μ M) were five times higher than those

- 30 -

which inhibit protein synthesis in HUVEC by greater than 95%, as measured by [³H]leucine uptake. Anisomycin alone had little effect on KDR/flk-1 expression at this dose. However, pretreatment with anisomycin significantly
5 blunted the effect of TNF- α on KDR/flk-1 expression (29% vs. 65%, $p < 0.05$), indicating that the effect of TNF- α on KDR/flk-1 in HUVEC was at least partly dependent on new protein synthesis. These results did not vary with the protein synthesis inhibitor used, as cycloheximide caused
10 an identical inhibition of the TNF- α effect. Our studies also show that the effect of TNF- α on flt1 expression is similarly protein synthesis-dependent in HUVEC.

TNF- α Decreased New KDR/flk-1 Protein Synthesis in HUVEC

Immunoprecipitation of ³⁵S-labeled HUVEC lysates
15 was performed to demonstrate the production of immunoreactive KDR/flk-1 protein by HUVEC and to determine whether the decrease in KDR/flk-1 mRNA was accompanied by a decrease in protein synthesis. A rabbit anti-human KDR/flk-1 antibody (Santa Cruz SC-xxx)
20 immunoprecipitated a single species with a molecular mass of approximately 205 kDa, consistent with the size of full length KDR/flk-1 protein when expressed in, and immunoprecipitated from, NIH 3T3 or COS7 cells (Quinn et al., 1993, Proc. Natl. Acad. Sci. USA 90(16):7533-7537;
25 Millauer et al., 1994, Nature 367(6463):576-579). An identically sized species was detected by an antibody raised against a different KDR/flk-1 epitope (Santa Cruz SC-xyx), but not by a rabbit antibody raised in a similar fashion to the transcription factor Sp1,
30 demonstrating the specificity of this interaction. Treatment of HUVEC with TNF- α for 12 hours increased ³⁵S-labeled KDR-flk-1 protein levels slightly (<40%), but reproducibly, raising the intriguing possibility that TNF- α also regulates KDR/flk-1 at the translational or
35 post-translational level. After 24 hours of TNF- α

- 31 -

treatment, ³⁵S-labeled KDR/flk-1 protein levels were decreased to 18% of control levels, confirming that the decrease in KDR/flk-1 mRNA induced by TNF- α is accompanied by a similar decrease in KDR/flk-1 protein expression (Fig. 12).

Use

The DNA of the invention promotes endothelial cell-specific transcription of DNA sequences to which it is operably linked. These promoter sequences are useful to direct or prevent the expression of genes specifically in endothelial cells. The invention provides the basis for novel therapeutic approaches to vascular diseases such as arteriosclerosis, as well as non-vascular diseases such as cancer, e.g., solid tumors, and inflammatory diseases, e.g., rheumatoid arthritis and diabetic retinopathy, as described in Examples 1 and 2 below.

The invention also provides methods for identifying compounds which (1) modulate TNF- α downregulation VEGF receptor (e.g., KDR/flk-1 or flt1) gene expression (Example 3, below), or (2) modulate TNF- α inhibition of VEGF-induced endothelial cell proliferation (Example 4). Compounds found to enhance TNF- α downregulation of expression of a VEGF receptor gene or enhance TNF- α inhibition of VEGF-induced endothelial cell proliferation can be used in methods to inhibit angiogenesis, while compounds found to enhance TNF- α downregulation of KDR/flk-1 or enhance TNF- α inhibition of VEGF-induced endothelial cell proliferation can be used in methods to promote angiogenesis, for example, to promote wound healing (e.g., healing of broken bones, burns, diabetic ulcers, and traumatic or surgical wounds) or to treat peripheral vascular disease, atherosclerosis, cerebral vascular disease, hypoxic tissue damage (e.g.,

- 32 -

hypoxic damage to heart tissue), diabetic pathologies such as chronic skin lesions, or coronary vascular disease. These compounds can also be used to treat patients who have, or have had, transient ischemic attacks, vascular graft surgery, balloon angioplasty, frostbite, gangrene, or poor circulation. As is described in Example 5, identification of the cis-acting sequences in the KDR/flk-1 gene required for downregulation by TNF- α provides the basis for additional therapeutic methods for these conditions.

Example 1: Gene Therapy

The invention can be used for gene therapy treatment of vascular diseases. The DNA of the invention can be used alone or as part of a vector to express heterologous genes, e.g., genes which encode proteins other than KDR/flk-1, in cells of the blood vessel wall, i.e., endothelial cells, for gene therapy of vascular diseases such as arteriosclerosis. The DNA or vector containing a sequence encoding a polypeptide of interest is introduced into endothelial cells which in turn produce the polypeptide of interest. For example, sequences encoding t-PA (Pennica et al., 1982, Nature 301:214), p21 cell cycle inhibitor (El-Deiry et al., 1993, Cell 75:817-823), or nitric oxide synthase (Bredt et al., 1990, Nature 347:768-770) may be operably linked to the endothelial cell-specific promoter sequences of the invention and expressed in endothelial cells. For example, thrombolytic agents can be expressed under the control of the endothelial cell-specific promoter sequences for expression by vascular endothelial cells in blood vessels, e.g., vessels occluded by aberrant blood clots. Other heterologous proteins, e.g., proteins which inhibit smooth muscle cell proliferation, e.g., interferon- γ and atrial natriuretic polypeptide, may be

- 33 -

specifically expressed in endothelial cells to ensure the delivery of these therapeutic peptides to an arteriosclerotic lesion or an area at risk of developing an arteriosclerotic lesion, e.g., an injured blood vessel.

The endothelial cell-specific promoter sequences of the invention may also be used in gene therapy to promote angiogenesis to treat diseases such as peripheral vascular disease or coronary artery disease (Isner et al., 1995, Circulation 91:2687-2692). For example, the DNA of the invention can be operably linked to sequences encoding cellular growth factors which promote angiogenesis, e.g., VEGF, acidic fibroblast growth factor, or basic fibroblast growth factor.

According to the invention, the DNA of the invention is located sufficiently close to the coding sequence to be transcribed that it functions to direct expression of the polypeptide in an endothelial cell. For example, SEQ ID NO:1, 2, and 3 are preferably located 5' to the transcription start site, and SEQ ID NO:4 is located 3' of the transcription start site. However, these sequences may be in any order relative to the transcription start site provided that endothelial cell-specific promoter activity is preserved.

Example 2: Antisense Therapy

The DNA of the invention may also be used in methods of antisense therapy. Antisense therapy may be carried out by administering to an animal, e.g., a human patient, DNA containing the endothelial cell-specific promoter sequences of the invention operably linked to a DNA sequence, i.e., an antisense template, which is transcribed into an antisense RNA. The antisense RNA may be a short (generally at least 10, preferably at least 14 nucleotides, and up to 100 or more nucleotides) nucleotide sequence formulated to be complementary to a

- 34 -

portion of a specific mRNA sequence. The antisense template is preferably located downstream from the promoter sequences of the invention. A poly A tail is typically located at the end of the antisense sequence to
5 signal the end of the sequence. Standard methods relating to antisense technology have been described (Melani et al., Cancer Res. 51:2897-2901, 1991). Following transcription of the DNA sequence into antisense RNA, the antisense RNA binds to its target mRNA
10 molecules within a cell, thereby inhibiting translation of the mRNA and down-regulating expression of the protein encoded by the mRNA. For example, an antisense sequence complementary to a portion of or all of the KDR-flk-1 mRNA (Terman et al., 1991, Oncogene 6:1677-1683) would
15 inhibit the expression of KDR-flk-1, which in turn would inhibit angiogenesis. Such antisense therapy may be used to treat cancer, particularly to inhibit angiogenesis at the site of a solid tumor, as well as other pathogenic conditions which are caused by or exacerbated by
20 angiogenesis, e.g., inflammatory diseases such as rheumatoid arthritis, and diabetic retinopathy.

The expression of other endothelial cell proteins may also be inhibited in a similar manner. For example, the DNA of the invention can be operably linked to
25 antisense templates which are transcribed into antisense RNA capable of inhibiting the expression of the following endothelial cell proteins: cell cycle proteins (thereby inhibiting endothelial cell proliferation, and therefore, angiogenesis); coagulation factors such as von Willebrand
30 factor; and endothelial cell adhesion factors, such as ICAM-1 and VCAM-1 (Bennett et al., 1994, J. Immunol. 152:3530-3540).

For gene therapy or antisense therapy, the claimed DNA may be introduced into target cells of an
35 animal, e.g., a patient, using standard vectors and/or

- 35 -

gene delivery systems. Suitable gene delivery systems may include liposomes, receptor-mediated delivery systems, naked DNA, and viral vectors such as herpes viruses, retroviruses, adenoviruses, and adeno-associated viruses, among others. Delivery of nucleic acids to a specific site in the body for gene therapy or antisense therapy may also be accomplished using a biolistic delivery system, such as that described by Williams et al., 1991, Proc. Natl. Acad. Sci. USA 88:2726-2729.

Standard methods for transfecting cells with isolated DNA are well known to those skilled in the art of molecular biology. Gene therapy and antisense therapy to prevent or decrease the development of arteriosclerosis or inhibit angiogenesis may be carried out by directly administering the claimed DNA to a patient or by transfecting endothelial cells with the claimed DNA ex vivo and infusing the transfected cells into the patient.

DNA or transfected cells may be administered in a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are biologically compatible vehicles which are suitable for administration to an animal, e.g., physiological saline. A therapeutically effective amount is an amount of the DNA of the invention which is capable of producing a medically desirable result in a treated animal. As is well known in the medical arts, dosages for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently. Dosages will vary, but a preferred dosage for intravenous administration of DNA is from approximately 10^6 to 10^{22} copies of the DNA molecule. The compositions of the invention may be administered locally or systemically. Administration will generally be parenterally, e.g., intravenously; DNA

- 36 -

may also be administered directly to the target site, e.g., by biolistic delivery to an internal or external target site or by catheter to a site in an artery.

Example 3: Identification of Compounds Which Modulate

5 TNF- α Downregulation of VEGF Receptor (KDR/flk-1 or flt1)
Gene Expression

As is discussed above, TNF- α downregulates expression of KDR/flk-1 and flt1 genes, each of which encodes a VEGF receptor. Thus, potentiating TNF- α
10 downregulation of KDR/flk-1 or flt1 expression can be useful in decreasing endothelial cell growth and, therefore, in inhibiting processes such as angiogenesis. Conversely, inhibiting TNF- α downregulation of KDR/flk-1 or flt1 expression can be useful in increasing
15 endothelial cell growth in order to promote angiogenesis, as would be desirable in promoting wound healing or in the treatment of peripheral vascular disease.

Modulation of endothelial cell growth can be achieved by administering a compound which blocks or
20 enhances TNF- α -mediated inhibition of KDR/flk-1 or flt1 expression. Such a compound can be identified by methods ranging from rational drug design to screening of random compounds. The latter method is preferable, as a simple and rapid assay for carrying out the method is available.
25 Small organic molecules are desirable candidate compounds for this analysis, as frequently these molecules are capable of passing through the plasma membrane so that they can potentially modulate TNF- α regulation of KDR/flk-1 or flt1 gene expression within the cell.

30 The screening of small, membrane-permeable organic molecules for the ability to modulate TNF- α downregulation of KDR/flk-1 or flt1 is carried out as follows. Cells expressing KDR/flk-1 or flt1 (e.g., HUVEC) are cultured in the presence of TNF- α and the
35 candidate compound. (Cells containing the KDR/flk-1 (or

- 37 -

flt1) promoter operably linked to a reporter gene may also be used in this method, provided that the promoter is active in the cells in the absence of TNF- α .) The level of KDR/flk-1 (or flt1) expression (as measured by, 5 e.g., Northern blot analysis (see above), RNase protection analysis, or other standard methods) in these cells is compared to the level in cells cultured with TNF- α , but without the candidate compound.

An increase in KDR/flk-1 (or flt1) expression 10 indicates identification of a compound which blocks TNF- α downregulation of KDR/flk-1 (or flt1) expression. As is mentioned above, such a compound can be used in the treatment of conditions in which enhancement of endothelial cell growth or angiogenesis is desired, e.g., 15 peripheral vascular disease, as well as for promoting wound healing. One specific condition in which angiogenesis is desired involves interruption of cardiac blood flow. In such situations, TNF- α may hinder the natural angiogenic process which could control damage to 20 cardiac tissue.

A decrease in KDR/flk-1 (or flt1) expression indicates identification of a compound which potentiates TNF- α downregulation of KDR/flk-1 expression. Such a compound can be used to treat conditions in which 25 decreased endothelial cell growth or angiogenesis is desired. For example, the growth of a tumor may be inhibited by treatment with such a compound.

Compounds identified as having the desired effect (i.e., enhancing or inhibiting TNF- α downregulation of 30 KDR/flk-1 or flt1 expression) can be tested further in appropriate models of endothelial cell growth and angiogenesis which are known to those skilled in the art.

The therapeutic compounds identified using the method of the invention may be administered to a patient 35 by any appropriate method for the particular compound,

- 38 -

e.g., orally, intravenously, parenterally, transdermally, transmucosally, or by surgery or implantation (e.g., with the compound being in the form of a solid or semi-solid biologically compatible and resorbable matrix) at or near
5 the site where the effect of the compound is desired. For example, a salve or transdermal patch that can be directly applied to the skin so that a sufficient quantity of the compound is absorbed to increase vascularization locally may be used. This method would
10 apply most generally to wounds on the skin. Salves containing the compound can be applied topically to induce new blood vessel formation locally, thereby improving oxygenation of the area and hastening wound healing. Therapeutic doses are determined specifically
15 for each compound, most administered within the range of 0.001 to 100.0 mg/kg body weight, or within a range that is clinically determined to be appropriate by one skilled in the art.

Example 4: Identification of Compounds Which Modulate
20 the Effect of TNF- α on VEGF-Induced Epithelial Cell Growth

As is discussed above, TNF- α inhibits VEGF-induced proliferation of endothelial cells (see, e.g., Fig. 8 and the corresponding text). Accordingly, compounds which
25 modulate the effect of TNF- α on VEGF-induced endothelial cell growth can be used to treat conditions associated with endothelial cell growth, such as angiogenesis. Such compounds can be identified using the methods described above. For example, endothelial cells can be cultured
30 with VEGF and TNF- α in the presence and absence of the candidate compound in order to determine whether the compound affects endothelial cell growth, which can be measured, e.g., by monitoring uptake of [3 H]thymidine. As is discussed above, compounds found to have the
35 desired effect (i.e., enhancing or inhibiting TNF- α

- 39 -

inhibition of VEGF-induced endothelial cell proliferation) can be tested further in appropriate models of endothelial cell growth and angiogenesis, which are known to those skilled in the art. Compounds

5 identified using this method are administered to patients as is described above in Example 3. This method may also be carried out without the addition of VEGF, in order to identify compounds which modulate the effect of TNF- α on the growth of endothelial cells in the absence of VEGF.

10 Example 5: Identification of the Cis-Acting Element in the KDR/flk-1 Gene Required for TNF- α Downregulation

Identification of the cis-acting element in the KDR/flk-1 gene required for TNF- α -mediated downregulation (the TNF- α -responsive element), as well as the trans-
15 acting factor which interacts with the TNF- α -responsive element, will form the basis for the development of novel therapeutics for modulating conditions associated with endothelial cell growth, such as angiogenesis, vascular disease, and wound healing.

20 Identification of the cis-acting elements of a gene, as well as the corresponding trans-acting factors, are carried out using standard methods in the art (see, e.g., Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor
25 Laboratory Press, Cold Spring Harbor, New York; Ausubel et al., eds., Current Protocols in Molecular Biology, Wiley & Sons, New York, 1989). For example, as a starting point, DNase I hypersensitivity experiments can be carried out in order to identify regions in the gene
30 which potentially bind regulatory factors.

Identification of the precise sequences of the cis-acting element (e.g., the TNF- α responsive element in the KDR/flk-1 gene) can be carried out using standard promoter deletion analysis. A construct including
35 KDR/flk-1 sequences that confer TNF- α downregulation to a

- 40 -

reporter gene to which the sequences are operably linked, can be progressively deleted, by 5', 3', and/or nested deletions, until the effect of TNF- α on the expression of the reporter gene in transfected cells is reduced.

5 Promoter deletion constructs, such as those described above, can be used to begin this analysis. To confirm the identification of the TNF- α -responsive element identified in the deletion studies, point mutations can be introduced into the element, using standard methods,
10 in the context of the full promoter.

The KDR/flk-1 TNF- α -responsive element can then be used as a tool for identifying trans-acting factors which bind to it, and thus are likely to be components of the pathway of TNF- α downregulation of KDR/flk-1. To
15 determine whether a protein binds to the element, standard DNA footprinting and/or native gel-shift analyses can be carried out. In order to identify the trans-acting factor which binds to the TNF- α -responsive element, the element can be used as an affinity reagent
20 in standard protein purification methods, or as a probe for screening an expression library. Once the trans-acting factor is identified, modulation of its binding to the TNF- α -responsive element in the KDR/flk-1 gene can be pursued, beginning with, for example, screening for
25 inhibitors of trans-acting factor binding. Enhancement of TNF- α downregulation of KDR/flk-1 expression in a patient, and thus inhibition of angiogenesis, may be achieved by administration of the trans-acting factor, or the gene encoding it (e.g., in a vector for gene
30 therapy). In addition, if the active form of the trans-acting factor is a dimer, dominant-negative mutants of the trans-acting factor could be made in order to inhibit its activity. Furthermore, upon identification of the TNF- α -responsive element in the KDR/flk-1 gene, and its
35 corresponding trans-acting factor, further components in

- 41 -

the TNF- α pathway of KDR/flk-1 downregulation can be identified. Modulation of the activities of these components can then be pursued, in order to develop additional drugs and methods for modulating endothelial
5 cell growth and angiogenesis. The methods described in this example can also be carried out with the flt1 gene.

Other Embodiments

In addition to antisense therapy for inhibition of angiogenesis, expression of KDR/flk-1 in endothelial
10 cells can also be carried out by inhibiting the binding of transcription factors, e.g., AP-2, SP-1 and NF κ B, to the cis-acting binding sites in the promoter sequences of the invention. For example, transcription can be inhibited using dominant negative mutants of
15 transcription factors, e.g., a dominant negative mutant of AP-2 which binds to the AP-1 binding site but fails to activate transcription. Alternatively, compounds which downregulate production of transcription factors, e.g., retinoic acid or dexamethasone which downregulate
20 production of AP-2 and NF κ B, can be administered to inhibit angiogenesis by inhibiting expression of KDR/flk-1.

- 42 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: President and Fellows of Harvard College
- (ii) TITLE OF INVENTION: TRANSCRIPTIONAL REGULATION OF GENES ENCODING
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS
- (iii) NUMBER OF SEQUENCES: 16
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Fish & Richardson P.C.
 - (B) STREET: 225 Franklin Street
 - (C) CITY: Boston
 - (D) STATE: MA
 - (E) COUNTRY: USA
 - (F) ZIP: 02110-2804
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: 08/573,692
 - (B) FILING DATE: DEC-18-1995
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 08/494,282
 - (B) FILING DATE: JUN-23-1995
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Fraser, Janis K.
 - (B) REGISTRATION NUMBER: 34,819
 - (C) REFERENCE/DOCKET NUMBER: 05433/021001
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 617/542-5070
 - (B) TELEFAX: 617/542-8906
 - (C) TELEX: 200154

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 62 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: both
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: DNA

- 43 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TTGTTGCTCT GGGATGTTCT CTCCTGGGCG ACTTGGGGCC CAGCGCAGTC CAGTTGTGTG 60
GG 62

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: both
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GCTGGCCGCA CGGGAGAGC 19

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: both
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GCTGGCCGCA CGGGAGAGCC CCTCCTCCGC CCCGGC 36

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: both
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GGATATCCTC TCCTACCGGC AC 22

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 493 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: both

- 44 -

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TTGTTGCTCT GGGATGTTCT CTCCTGGGCG ACTTGGGGCC CAGCGCAGTC CAGTTGTGTG	60
GGGAAATGGG GAGATGTAAA TGGGCTTGGG GAGCTGGAGA TCCCCGCCGG GTACCCGGGT	120
GAGGGGCGGG GCTGGCCGCA CGGGAGAGCC CCTCCTCCGC CCCGGCCCCG CCCC GCATGG	180
CCCCGCCTCC GCGCTCTAGA GTTTCGGCTC CAGCTCCCAC CCTGCACTGA GTCCCGGGAC	240
CCCGGGAGAG CGGTCAGTGT GTGGTCGCTG CGTTTCCTCT GCCTGCGCCG GGCATCACTT	300
GCGCGCCGCA GAAAGTCCGT CTGGCAGCCT GGATATCCTC TCCTACCGGC ACCCGCAGAC	360
GCCCCTGCAG CCGCCGGTCG GCGCCCGGGC TCCCTAGCCC TGTGCGCTCA ACTGTCCTGC	420
GCTGCGGGGT GCCGCGAGTT CCACCTCCGC GCCTCCTTCT CTAGACAGGC GCTGGGAGAA	480
AGAACCGGCT CCC	493

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 352 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TTGTTGCTCT GGGATGTTCT CTCCTGGGCG ACTTGGGGCC CAGCGCAGTC CAGTTGTGTG	60
GGGAAATGGG GAGATGTAAA TGGGCTTGGG GAGCTGGAGA TCCCCGCCGG GTACCCGGGT	120
GAGGGGCGGG GCTGGCCGCA CGGGAGAGCC CCTCCTCCGC CCCGGCCCCG CCCC GCATGG	180
CCCCGCCTCC GCGCTCTAGA GTTTCGGCTC CAGCTCCCAC CCTGCACTGA GTCCCGGGAC	240
CCCGGGAGAG CGGTCAGTGT GTGGTCGCTG CGTTTCCTCT GCCTGCGCCG GGCATCACTT	300
GCGCGCCGCA GAAAGTCCGT CTGGCAGCCT GGATATCCTC TCCTACCGGC AC	352

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1267 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- 45 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CCTCCTTCCC CTGGGCCTAA GGATATCTTG GCTGGAAGCT CTGCTCTGAA AAGGGGCATG	60
GCCAAACTTT CACTAGGGCT CTTCGTTGGG GAGCACGATG GACAAAAGCC TTCTTGGGGC	120
TAGGCAGGTC ACTTCAAAC TGGAGCCGCC AAATATTTTG GGAAATAGCG GGAATGCTGG	180
CGAACTGGGC AAGTGCCTTT TCTGATTAAG AGCAACCAGA TTCAGCTTTT TAAACTACAA	240
TTATACTGGC CAAACAAAAT ACCCTTATAC AAAAACCAAA ACTACTGGCA GGAGTCGCTG	300
CCAGCTTGCG ACCCGGCATA CTGGGCTGAG TATCCGCTTC TCCCTTGTGG CTGGAAACTG	360
ATGCAGATTC TCGGCCACTT CAGACGCGCG CGATGGCGAA GAGGGTCCTG CACTTTGACG	420
CGCCTGGTGA GGGAGCGGTG CTCTTCGCAG CGCTCCTGGT GATGCTCCCC AAATTTCGGG	480
GACCGGCAAG CGATTAAATC TTGGAGTTGC TCAGCGCCCG TTACCGAGTA CTTTTTATTT	540
ACACCAGAAA CAAAGTTGTT GCTCTGGGAT GTTCTCTCCT GGGCGACTTG GGGCCCAGCG	600
CAGTCCAGTT GTGTGGGGAA ATGGGGAGAT GTAAATGGGC TTGGGGAGCT GGAGATCCCC	660
GCCGGGTACC CGGGTGAGGG GCGGGGCTGG CCGCACGGGA GAGCCCCTCC TCCGCCCCGG	720
CCCCGCCCCG CATGGCCCCG CCTCCGCGCT CTAGAGTTTC GGCTCCAGCT CCCACCCTGC	780
ACTGAGTCCC GGGACCCCGG GAGAGCGGTC AGTGTGTGGT CGCTGCGTTT CCTCTGCCTG	840
CGCCGGGCAT CACTTGCGCG CCGCAGAAAG TCCGTCTGGC AGCCTGGATA TCCTCTCCTA	900
CCGGCACCCG CAGACGCCCC TGCAGCCGCC GGTCGGCGCC CGGGCTCCCT AGCCCTGTGC	960
GCTCAACTGT CCTGCGCTGC GGGGTGCCGC GAGTTCCACC TCCGCGCCTC CTTCTCTAGA	1020
CAGGCGCTGG GAGAAAGAAC CGGCTCCCGA GTTCTGGGCA TTTCGCCCCG CTCGAGGTGC	1080
AGGATGCAGA GCAAGGTGCT GCTGGCCGTC GCCCTGTGGC TCTGCGTGGA GACCCGGGCC	1140
GCCTCTGTGG GTAAGGAGCC CACTCTGGAG GAGGAAGGCA GACAGGTCGG GTGAGGGCGG	1200
AGAGGACCTG AAAGCCAGAT CTAATCGGA ATCGTAGAGC TGGAGAGTTG GACAGGACTT	1260
GACATTT	1267

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 500 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: both
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

- 46 -

ACTTCTACCA GAAACCGAGC TCGTCCAGA TTTGCTCTCA GATGCGACTT GCCGCCCGGC 60
ACAGTCCGGG GTAGTGGGGG AGTGGGCGTG GGAAACCGGG AAACCCAAAC CTGGTATCCA 120
GTGGGGGGCG TGGCCGGACG CAGGGAGTCC CCACCCCTCC CGGTAATGAC CCCGCCCCCA 180
TTCGCTAGTG TGAGCCGGC GCTCTCTTTC TGCCCTGAGT CCTCAGGACC CCAAGAGAGT 240
AAGCTGTGTT TCCTTAGATT CGGGGACCGC TACCCGGCAG GACTGAAAGC CCAGACTGTG 300
TCCCGCAGCC GGGATAACCT GGCTGACCCG ATTCCGCGGA CACCGCTGCA GCCGCGGCTG 360
GAGCCAGGGC GCCGGTGCCC CGCGCTCTCC CCGGTCTTGC GAAGGAGTCT GTGCCTGAGA 420
AACTGGGCTC TGTGCCCAGG CGCGAGGTGC AGGATGGAGA GCAAGGCGCT GCTAGCTGTC 480
GCTCTGTGGT TCTGCGTGA 500

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: both
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CTGTCTAGAG AAGGAGGCGC GGAGGTGGAA CT 32

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: both
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

TCTGGCAGCC TGGTCGTCCT CTCCTA 26

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: both
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- 47 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

TAGGAGAGGA CGACCAGGCT GCCAGA

26

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: both

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

TGCCTCGACT TGTGCTCTG GGATGTT

27

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: both

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

TGTAAGCTTG GGAGCCGGTT CTTTCTC

27

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: both

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CCCTGCACTG A

11

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

- 48 -

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Met Gln Ser Lys Val Leu Leu Ala Val Ala Leu Trp Leu Cys Val Glu
1 5 10 15

Thr Arg Ala Ala Ser Val
20

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Met Glu Ser Lys Ala Leu Leu Ala Val Ala Leu Trp Phe Cys Val Lys
1 5 10 15

Other embodiments are within the following claims.

What is claimed is:

-49-

CLAIMS:

1. A substantially pure DNA comprising a sequence substantially identical to SEQ ID NO:1, wherein said DNA regulates endothelial cell-specific transcription of a polypeptide-encoding sequence to which
5 it is operably linked.

2. The DNA of claim 1, wherein said DNA further comprises a sequence substantially identical to SEQ ID NO:2 or a sequence substantially identical to SEQ ID NO:3.

10 3. The DNA of claim 1, wherein said DNA further comprises a sequence substantially identical to SEQ ID NO:4.

4. The DNA of claim 2, wherein said DNA further comprises a sequence substantially identical to SEQ ID
15 NO:4.

5. A substantially pure DNA comprising a sequence substantially identical to SEQ ID NO:6, wherein said DNA regulates endothelial cell-specific transcription of a polypeptide-encoding sequence to which
20 it is operably linked.

6. A substantially pure DNA comprising a sequence substantially identical to SEQ ID NO:5, wherein said DNA regulates endothelial cell-specific transcription of a polypeptide-encoding sequence to which
25 it is operably linked.

7. The DNA of claim 1, wherein said DNA is operably linked to said polypeptide-encoding sequence and functions to regulate endothelial cell-specific transcription of said polypeptide-encoding sequence.

- 50 -

8. The DNA of claim 7, wherein said polypeptide-encoding sequence does not encode KDR/flk-1.

9. The DNA of claim 8, wherein said polypeptide is chosen from a group consisting of tissue plasminogen
5 activator, p21 cell cycle inhibitor, nitric oxide synthase, interferon- γ , and atrial natriuretic polypeptide.

10. A vector comprising the DNA of claim 8.

11. A method of directing endothelial cell-
10 specific expression of a polypeptide, comprising introducing into an endothelial cell the vector of claim 10.

12. An endothelial cell comprising the vector of claim 10.

13. A method of inhibiting arteriosclerosis in an
15 animal, comprising contacting an artery of said animal with the vector of claim 10, wherein said polypeptide reduces or prevents the development of arteriosclerosis.

14. The method of claim 13, wherein said
20 polypeptide reduces proliferation of smooth muscle cells.

15. A substantially pure DNA with a sequence substantially identical to SEQ ID NO:1, wherein said DNA regulates endothelial cell-specific transcription of an
- - - - - antisense template to which it is operably linked.

16. The DNA of claim 15, wherein said DNA is
25 operably linked to said antisense template and wherein

- 51 -

said DNA functions to regulate endothelial cell-specific transcription of said antisense template.

17. The DNA of claim 16, wherein said antisense template is complementary to an mRNA encoding an
5 endothelial cell polypeptide.

18. The DNA of claim 14, wherein said endothelial cell polypeptide is KDR/flk-1.

19. The DNA of claim 17, wherein said endothelial cell polypeptide is chosen from a group consisting of a
10 cell cycle protein, a coagulation factor, and a cell adhesion factor.

20. A method of treating cancer in an animal, comprising contacting a tumor site in said animal with the DNA of claim 18, wherein said DNA reduces or prevents
15 angiogenesis at said tumor site.

21. A method of measuring the ability of a candidate compound to modulate TNF- α downregulation of expression of a vascular endothelial growth factor receptor gene, said method comprising the steps of:
20 (a) providing a cell comprising the promoter of said vascular endothelial growth factor receptor gene operably linked to a reporter gene;
(b) culturing said cell in the presence of TNF- α and said candidate compound; and
25 (c) determining the level of expression of said reporter gene as a measure of the ability of said candidate compound to modulate TNF- α downregulation of expression of said vascular endothelial growth factor receptor gene.

- 52 -

22. A method of measuring the ability of a candidate compound to modulate TNF- α inhibition of VEGF-induced endothelial cell proliferation, said method comprising the steps of:

- 5 (a) providing an endothelial cell;
- (b) culturing said cell in the presence of TNF- α , VEGF, and said candidate compound; and
- (c) determining the level of endothelial cell growth as a measure of the ability of said candidate
- 10 compound to modulate TNF- α inhibition of VEGF-induced endothelial cell proliferation.

23. A method of inhibiting angiogenesis in a patient, said method comprising administering to said patient a non-TNF- α compound which activates the TNF- α

15 pathway of downregulating expression of a vascular endothelial growth factor receptor gene in an endothelial cell.

24. A method of enhancing angiogenesis in a patient, said method comprising administering to said

20 patient a non-TNF- α compound which inhibits the TNF- α pathway of downregulating expression of a vascular endothelial growth factor receptor gene in an endothelial cell.

25. A method of inhibiting angiogenesis in a

25 patient, said method comprising administering to said patient a polypeptide which inhibits expression of a vascular endothelial cell growth factor receptor gene in an endothelial cell by binding to the TNF- α -responsive element in the promoter of said vascular endothelial cell

30 growth factor receptor gene.




FIG. 1A




FIG. 1B

3/13






FIG. 2A

FIG. 2B**FIG. 2C**




FIG. 3A




FIG. 3B




FIG. 4A

Luciferase activity (% of pGL2 Control)




FIG. 4B

7/13




FIG. 5




FIG. 6A





FIG. 6B

9/13

**FIG. 7**





FIG. 11

11/13

FIG. 9A





FIG. 9B

FIG. 10A






FIG. 10B



Immunoprecipitable
flk-1 protein
is decreased
by TNF-α

FIG. 12

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/11, A61K 31/70, C07H 21/00	A2	(11) International Publication Number: WO 95/04142 (43) International Publication Date: 9 February 1995 (09.02.95)
(21) International Application Number: PCT/US94/08537 (22) International Filing Date: 26 July 1994 (26.07.94) (30) Priority Data: 08/098,942 27 July 1993 (27.07.93) US (60) Parent Application or Grant (63) Related by Continuation US 08/098,942 (CIP) Filed on 27 July 1993 (27.07.93) (71) Applicant (for all designated States except US): HYBRIDON, INC. [US/US]; One Innovation Drive, Worcester, MA 01605 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): ROBINSON, Gregory, S. [US/US]; 194 School Street, Acton, MA 01720 (US). (74) Agent: GREENFIELD, Michael, S.; Allegretti & Witcoff, Ltd., Ten South Wacker Drive, Chicago, IL 60606 (US).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: ANTISENSE OLIGONUCLEOTIDE INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION		
(57) Abstract Vascular Endothelial Growth Factor (VEGF), also known as vascular permeability factor (VPF), has been shown to play in integral role in abnormal angiogenesis associated with a variety of pathological states. This disclosure presents compounds, compositions, and methods for inhibiting such abnormal angiogenesis. In particular, this disclosure presents several antisense oligonucleotides from 19 to 21 bases long that bind to VEGF RNA and inhibit production of the expression product. These antisense oligonucleotides are useful in the treatment of pathological states in which VEGF expression plays a role.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

ANTISENSE OLIGONUCLEOTIDE INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION

BACKGROUND OF THE INVENTION

Field of the Invention

This invention relates to the field of antisense oligonucleotides for use in the inhibition of vascular endothelial cell growth factor (VEGF) expression.

5 Description of Related Art

Vascular endothelial cell growth factor (VEGF), also known as vascular permeability factor (VPF), is a 34-43 kDa (with the predominant species at about 45 kDa) dimeric, disulphide-linked glycoprotein synthesized and secreted by a variety of tumor and normal cells. Leung et al., *Science* 246, 1306 (1989), observed three
10 VEGF transcripts (121, 165, and 189 amino acids long, respectively), suggesting that an alternative splicing mechanism is involved. More recently, Houck et al. discovered a fourth VEGF transcript having a length of 206 amino acids. Tischer et al., *J. Biol. Chem.* 266, 11947 (1991), have determined that the human VEGF coding region is comprised of eight exons. Furthermore, this group proved that three mRNA
15 transcripts (encoding for the 121, 165, and 189 amino acid long peptides) were the result of alternative splicing. Transcripts analogous to the 121 and 165 amino acid polypeptides have been identified in the bovine system. Leung et al., *supra*. The transcript corresponding to the 165 amino acid transcript have also been identified in the rodent system -- rat (Conn et al., *Proc. Natl. Acad. Sci. U.S.A.* 87, 2628 (1989)),
20 guinea pig (Sanger et al., *Cancer Res.* 50, 1774 (1990)), and mouse (Claffey et al., *J. Biol. Chem.* 257, 16317 (1992)).

Tischer et al., *supra*, reported the nucleic acid sequence for three forms of human VEGF coding region. Claffey et al., *supra*, published the sequence for murine VEGF. Comparisons have revealed greater than 85% interspecies conservation of the VEGF molecule. All the alternatively spliced VEGF molecules have not been identified yet, but based on the conservation between species, they should be in the near future.

The following discussion presents several pathological states in which VEGF is involved and emphasizes the importance of VEGF as a potential target for therapeutic treatment.

10 Diabetic Retinopathy

Diabetic retinopathy is the leading cause of blindness among working age adults (20-64) in the United States. During the course of Diabetes Mellitus, one complication that can arise is an occlusion of the retinal veins. This venous occlusion results in the formation of microaneurysms due to the expansion of the vessel wall, hemorrhaging (leaking of blood into surrounding areas), "cotton wool" spots representing cellular exudates (i.e., cellular damage) and neovascularization of the retina extending into the vitreous, resulting in bleeding. Classic treatments for diabetic retinopathy are 1) the control of blood glucose and blood pressure and 2) pan retinal laser photocoagulation (PRP). Treatment #1 can prolong the onset of the disease depending on the diligence of the affected individual. Treatment #2 is quite effective, but can lead to additional hemorrhaging as well as damage to critical areas needed for visions (i.e., foveal fibers). Additional treatments for this disease which have less side effects would prove extremely valuable.

Recent observations have shown an increase in VEGF protein levels in retinal

membranes from patients with diabetes, suggesting that this cytokine/growth factor may play an important role in the disease. The following characteristics of VEGF provide evidence that it may be an important regulator of diabetic retinopathy: (1) The action of VEGF is specific for endothelial cells; (2) VEGF has been shown to be angiogenic as well as mitogenic; (3) VEGF is a secreted molecule; (4) VEGF induces vascular permeability; and 5) VEGF is induced under hypoxic conditions (i.e., during retinal vein occlusion).

Atherosclerotic Plaque Formation

VEGF may play a role in the development of an atherosclerotic plaque. Atherosclerosis describes a state where the formation of lipid-containing lesions occurs in medium and large arteries. It is the primary cause of myocardial and cerebral infarctions in the United States. Lesions form within the intima, the innermost layer of the arterial wall, and are separated into two forms: the fatty streak (early), and the fibrous plaque (advanced). Both of these forms are characterized by lipid-filled macrophages (derived from blood-borne monocytes) and smooth muscle cells. The fibrous plaque is further characterized by the deposition of connective tissue and cholesterol crystals. These lesions occlude the lumen of the blood vessel diminishing the blood flow, leading to ischemia and necrosis. Research has shown that neovascularization can also occur in the atherosclerotic lesion. Levels of VEGF protein in these affected areas have not been determined, but it has been shown that both monocytes and macrophages express VEGF.

Wound Healing

VEGF may also be important in maintaining normal states of wound healing.

See Brown et al., *J. Exp. Med.* 176, 1375 (1992). Wound healing is usually a regulated response to injury or trauma. Focal hemorrhaging is followed by the extravasation (leaking) of fibrinogen from the plasma to form a fibrin gel or clot. This initial matrix is replaced by granulation tissue (fibronectin, collagen, proteoglycan) and finally by scar tissue. In addition, keratinocytes migrate and form a covering to protect against fluid loss and bacterial infection. One major characteristic of wound healing is that vessel hyperpermeability occurs for some time after bleeding has stopped. In addition, angiogenic activity is detectable during this time period. Recent work has shown that keratinocytes, located at the border of the wound as well as in the wound covering, produce VEGF. Brown et al., *supra*. This result suggests that VEGF may be responsible for hyperpermeable and angiogenic activity associated with wound healing.

Aberrant wound healing associated with surgery can result in complications such as hypertrophic scarring (excessive collagen deposition), keloid formation (scar tissue invading normal surrounding tissue), and adhesions in the peritoneal cavity. Other problems related with unregulated wound healing occur during the formation of lung fibrosis and in diabetes mellitus (wounds do not heal). It is believed that VEGF plays a role in these processes as well.

Tumor Angiogenesis

VEGF may be a tumor angiogenesis factor. Plate et al., *Nature* 359, 845 (1992). Angiogenesis is the tightly regulated processes by which new blood vessels develop. The development of a vascular system is necessary for the flow of nutrients and waste to and from tissues and organs. Smaller solid tumors (< 1-2 mm) do not require an extensive vascular system to survive, but instead derive their nourishment

through the diffusion of needed nutrients. However, in order for these cell masses to grow beyond several millimeters in size, additional vascularization is needed. See, e.g., Folkman, J. *Natl. Cancer Inst.* 82, 4 (1990). It has been suggested that inhibition of tumor angiogenesis might be an effective strategy to combat tumor growth and circumvent acquired resistance to traditional anti-cancer therapeutic agents. Kerbel, *BioEssays* 13, 31 (1991). Kim et al., *Nature* 362, 841 (1993) reported that monoclonal antibodies specific for VEGF inhibited the growth of tumors *in vivo*.

The tumor stroma, which contains both connective tissue and the vascular system, is essentially the "lifeline" of the tumor. Whereas normal tissue vasculature is organized and can respond to changes in metabolism, the tumor stroma is poorly organized and closely resembles scar tissue found during wound healing. The tumor stroma may represent only a small portion of the total tumor (e.g., medullary carcinoma of the breast) or may exist as 80-90% of the total cell mass (e.g., desmoplastic carcinoma). Tumor blood vessels also differ from those found in normal tissue in that they are hyperpermeable to plasma and plasma proteins. Whereas this porosity is seen in normal tissue only during wound healing, solid tumors maintain this porous characteristic indefinitely.

While a necessary component for tumor growth, the stroma also acts as a barrier against macromolecules (e.g., monoclonal antibodies) which are needed in sufficient quantities to be effective as therapeutic agents. In large tumors, antibodies/macromolecules may not be effective due to large diffusional spaces as well as absorption into perivascular regions of peripheral tumor cells. Consequently, an alternative therapeutic compound is desirable.

As just discussed, VEGF is principal component in many pathological states

and processes. Research has shown that VEGF is present in regions of tumors where capillary growth is occurring and suggests that VEGF can trigger the entire sequence of events leading to angiogenesis. By contrast, VEGF levels in normal tissues is relatively low. Regulation of the levels of VEGF expression, therefore, could prove to be an important method of treating pathological conditions without significantly affecting normal tissue. For instance, it follows from the earlier discussion that inhibition of VEGF expression may play an important role in (a) regulating the ocular complications associated with diabetic retinopathy, (b) regulating the formation of an atherosclerotic plaque, (c) controlling certain unregulated instances relating to wound healing processes, and (d) preventing and altering angiogenesis associated with tumor growth and metastasis. These, of course, are but examples of the diseased states in which VEGF is involved and for which regulation of VEGF expression could prove useful. Other pathologic states brought about (in part) by VEGF expression are also potential candidates for treatment by regulation of VEGF expression.

Antisense oligonucleotide technology may provide a novel approach to the inhibition of VEGF expression. *See generally Agrawal, Trends in Biotech.* 10, 152 (1992). By binding to the complementary nucleic acid sequence (the sense strand), antisense oligonucleotides are able to inhibit splicing and translation of RNA. In this way, antisense oligonucleotides are able to inhibit protein expression. Antisense oligonucleotides have also been shown to bind to genomic DNA, forming a triplex, and inhibit transcription. Furthermore, a 17-mer base sequence statistically occurs only once in the human genome, and thus extremely precise targeting of specific sequences is possible with such antisense oligonucleotides.

In 1978 Zamecnik and Stephenson were the first to propose the use of synthetic antisense oligonucleotides for therapeutic purposes. Stephenson and Zamecnik, *Proc. Natl. Acad. Sci. U.S.A.* 75, 285 (1978); Zamecnik and Stephenson, *Proc. Natl. Acad. Sci. U.S.A.* 75, 280 (1978). They reported that the use of a
5 oligonucleotide 13-mer complementary to the RNA of Rous sarcoma virus inhibited the growth of the virus in cell culture. Since then, numerous other studies have been published manifesting the *in vitro* efficacy of antisense oligonucleotide inhibition of viral growth, e.g., vesicular stomatitis viruses (Leonetti et al., *Gene* 72, 323 (1988)), herpes simplex viruses (Smith et al., *Proc. Natl. Acad. Sci. U.S.A.* 83, 2787 (1986)), and
10 influenza virus (Zerial et al., *Nucleic Acids Res.* 15, 9909 (1987)).

Antisense oligonucleotides have also been shown to inhibit protein expression in mammalian systems. For example, Burch and Mahan, *J. Clin. Invest.* 88, 1190 (1991), disclosed antisense oligonucleotides targeted to murine and human IL-1 receptors that inhibited IL-1-stimulated PGE₂ synthesis in murine and human
15 fibroblasts, respectively; Colige et al., *Biochemistry* 32, 7 (1993) disclosed antisense oligonucleotides that specifically inhibited expression of a mutated human procollagen gene in transfected mouse 3T3 cells without inhibiting expression of an endogenous gene for the same protein; and Monia et al., *J. Biol. Chem.* 267, 19954 (1992), disclosed selective inhibition of mutant Ha-*ras* mRNA expression with
20 phosphorothioate antisense oligonucleotide.

In most cases, however, unmodified antisense oligonucleotides are unsuitable for use in *in vivo* systems because of their susceptibility to attack by nucleases. Consequently, there has been much research in the area of modifying oligonucleotides to make them immune to such attack, thereby stabilizing the

molecules for *in vivo* use. See generally Uhlmann and Peymann, *Chemical Reviews* 90, 543 (1990) at pages 545-561 and references cited therein. Focus has been on modifying the internucleotide phosphate residues, modifying the nucleoside units, modifying the 2' position and substituting other moieties for the internucleotide phosphate. For example, Padmapriya and Agrawal, *Bioorg. & Med. Chem. Lett.* 3, 761 (1993) disclosed synthesis of oligodeoxynucleoside methylphosphonothioates; Temsamani et al., *Ann. N.Y. Acad. Sci.* 660, 318 (1992) disclosed certain 3' end-capped oligodeoxynucleotide phosphorothioates; and Tang et al., *Nucleic Acids Res.* 21, 2729 (1993) disclosed self-stabilized antisense oligodeoxynucleotide phosphorothioates having a hair-pin loop structure at their 3' ends.

Many modified antisense oligonucleotides are capable of withstanding nucleolytic degradation, yet are still capable of hybridizing to target sequences and, thus, inhibiting protein expression. These modified oligonucleotides are better suited for *in vivo* applications. Tang et al., *supra*, showed that self-stabilized antisense oligonucleotides showed greater *in vivo* stability than their linear counterparts in mice. Simons et al. *Nature* 359, 67 (1992) reported the use of two antisense *c-myc* phosphorothioate oligonucleotides that suppressed intimal accumulation of rat carotid arterial smooth muscle cells *in vivo*.

The oligonucleotides disclosed by Pederson et al. in U.S. Patent No. 5,220,007 ('007) is another modified antisense oligonucleotide that may be particularly well-suited for both *in vitro* and *in vivo* inhibition of protein expression. That molecule comprises an internal sequence having two or more consecutive, modified or unmodified, phosphodiester linkages. The internal sequence is flanked on both sides by modified nucleic acid sequences. The internal sequence activates RNase H, while

the flanking sequences are unable to activate RNase H. The result is that when the oligonucleotide of the '007 patent is bound to the target mRNA sequence, RNase H will excise the region of the target sequence complementary to the internal sequence of the antisense oligonucleotide. The target mRNA is thereby inactivated and protein expression inhibited.

Similarly, 3' end-capped (Temisamani et al., *supra*) and self-stabilized 3' hair-pin loop (Tang et al., *supra*) antisense oligonucleotides have been shown to have increased stability to nucleolytic attack and therefore may be well suited for inhibition of protein expression. The 3' hair-pin loop structure of Tang et al. is characterized as having a 3'-terminal sequence that is substantially complimentary and anneals to an internal sequence.

There is another convincing rationale behind the use of antisense oligonucleotide inhibition of VEGF expression to control angiogenesis. Whereas macromolecules such as monoclonal antibodies may have difficulty in reaching their target site at an effective concentration, antisense oligonucleotides can more easily enter cells/cell masses and accumulate at inhibiting concentrations. Antisense inhibition of VEGF is likely to provide an important tool in altering the development of abnormal angiogenesis.

Inhibition of VEGF expression by means of antisense oligonucleotide technology will also be useful in determining the role of this cytokine in processes where angiogenesis is involved. *In vitro* systems which mimic blood vessel formation/permeability have been developed. The role of VEGF in these systems can be determined using antisense oligonucleotides. Other *in vitro* systems, in use or being designed, can benefit from this technology. There are several areas where the

role of VEGF has not been determined. If inhibition of VEGF does not reduce tumor growth, it does not mean other systems (psoriasis, fertilizations-implantation, vascularization of the endometrium) should not be investigated.

SUMMARY OF THE INVENTION

5 Vascular Endothelial Growth Factor (VEGF) has been shown to play an integral role in angiogenesis associated with a variety of pathological conditions. An object of the present invention is to suppress angiogenesis associated with pathological conditions. A further object of the present invention is to provide useful compounds, compositions and methods for preventing the expression of VEGF
10 associated with these states. A still further object of the present invention is to provide compounds, compositions and methods for the treatment of these pathological states.

 Accordingly, this disclosure presents antisense oligonucleotides that have been constructed and are targeted to bind to nucleic acid sequences encoding VEGF,
15 thereby blocking production of the expression product. Also presented are methods for inhibiting VEGF expression and angiogenesis using these oligonucleotides, both *in vitro* and *in vivo*.

BRIEF DESCRIPTION OF THE DRAWINGS

 The foregoing and other objects of the present invention, the various features
20 thereof, as well as the invention itself may be more fully understood from the following description, when read together with the accompanying drawings in which:

 Figure 1 shows the results of the RNase H binding assay.

 Figure 2 shows the immunoprecipitation results of the Example 2, showing the

in vitro inhibition of murine VEGF expression in transfected COS-1 cells, which stably express VEGF.

Figure 3 shows the immunoprecipitation results of the Example 3, showing the *in vitro* inhibition of VEGF expression in murine NB41 cells, which endogenously express VEGF.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

Several novel antisense oligonucleotide phosphorothioates have been found that bind to murine VEGF RNA and inhibit VEGF expression *in vitro*. Inhibition of VEGF expression was found for antisense oligonucleotides targeted to the translational start and stop sites, as well as to internal coding regions of the VEGF mRNA. The oligonucleotides disclosed in the present invention range from 19 to 21 bases in length, but it is expected that variations in the length of the oligonucleotide can be made without substantially affecting the anti-VEGF properties of the molecule. The preferred antisense oligonucleotides of the present invention are 5'-CAGCCTGGCTCACCGCCTTGG-3' (SEQ ID NO 2) (Vm), 5'-CATGGTTTCGGAGGGCGTC-3' (SEQ ID NO 3) (JG-4), 5'-CACCCAAGAGAGCAGAAAGT-3' (SEQ ID NO 4) (JG-6), and 5'-TCGTGGGTGCAGCCTGGGAC-3' (SEQ ID NO 5) (JG-7).

Synthesis of the oligonucleotides of the present invention was done on a Pharmacia Gene Assembler series synthesizer using the phosphoramidite procedure. See, e.g., Uhlmann and Peymann at pp. 550-551 and references cited. Following assembly and deprotection, oligonucleotides were ethanol precipitated twice, dried, and resuspended in phosphate-buffered saline (1 X PBS) at the desired

concentration. These relatively short oligonucleotides, however, may be produced by any convenient method. Several such methods are well known in the art. *See supra*.

The nucleic sequence of murine VEGF is known. Claffey et al., *supra*. The sequence 5'-CAGCCTGGCTCACCGCCTTGG-3' (SEQ ID NO 2) (Vm) is targeted
5 to the sequence surrounding the translational stop site. The sequence 5'-CATGGTTTCGGAGGGCGTC-3' (SEQ ID NO 3) (JG-4) is targeted to the sequence 5' to and containing the ATG of the translational start site of the murine VEGF molecule. The sequence 5'-CACCCAAGAGAGCAGCAGAAAGT-3' (SEQ ID NO 4) (JG-6) is targeted against sequences containing codons 2-7 of the murine
10 VEGF molecule. The sequence 5'-TCGTGGGTGCAGCCTGGGAC-3' (SEQ ID NO 5) (JG-7) is targeted against sequences containing codons 24-29 of the murine VEGF molecule. These targeted regions of the VEGF nucleic acid sequence are conserved among all the four VEGF transcripts, resulting in complete inhibition of VEGF expression.

15 Positive identification of regions of the murine VEGF nucleic acid sequence whose corresponding antisense oligonucleotides inhibit VEGF expression suggests that the human antisense oligonucleotides targeted to the corresponding regions in the human VEGF nucleic acid sequence will inhibit VEGF expression in human cells. These assertions are supported by the high degree of homology between species. The
20 corresponding human VEGF antisense oligonucleotides are 5'-CAGCCCGGCTCACCGCCTCGG-3' (SEQ ID NO: 11) (targeted to the sequence surrounding the translational stop site), 5'-CATGGTTTCGGAGGCCCCGA-3' (SEQ ID NO: 12) (targeted to the sequence 5' to and containing the ATG of the translational start site of the human VEGF molecule.), 5'-

CACCCAAGACAGCAGAAAGT-3' (SEQ ID NO; 13) (targeted against sequences containing codons 2-7 of the human VEGF molecule), and 5'-CCATGGGTGCAGCCTGGGAC-3' (SEQ ID NO: 17) (targeted against sequences containing codons 24-29 of the human VEGF molecule). These antisense oligonucleotides are expected to inhibit VEGF expression in human cells in much the same way as the murine antisense oligonucleotides of the present invention inhibit expression of VEGF in mouse cells.

Exon-intron boundaries are potentially useful targets for antisense inhibition of VEGF expression. With the published nucleic acid sequences and this disclosure provided, those of skill in the art will be able to identify, with only a minimum of experimentation, those antisense nucleic acid sequences that inhibit VEGF expression.

Those of skill in the art will also understand that certain modifications of internucleotide linkages of an antisense oligonucleotide can be made without negatively affecting its efficacy in the inhibition of VEGF. Indeed, some modifications may improve the efficacy of inhibition. Many types of modifications are well known to those of skill in the art and, following the teachings of this disclosure, those suitable for both *in vitro* and *in vivo* suppression of VEGF expression can be easily produced. Among the modifications contemplated by the present invention are the 3' end-capped structure, the self-stabilized 3' hair-pin loop structure, and the modification consisting of an internal RNase H-activating sequence flanked by two sequences unable to activate RNase H, all described previously. Other modified internucleotide linkages suitable for use in the present invention are the methylphosphonate and phosphoramidate linkages, which are described in

Uhlmann and Peymann, *supra*. Other stabilizing modifications are also contemplated by the present invention and will be appreciated by those of skill in the art.

It is expected that *in vivo* inhibition of VEGF expression and abnormal angiogenesis can be achieved by administration of the antisense oligonucleotide phosphorothioates of the present invention to mammals. Administration into a mouse suffering from tumor angiogenesis can be by slow infusion pump at a rate of about 0.5 - 3.0 nMoles/hr (about 0.15-1.0 mg of an oligonucleotide 20-mer per kg of body weight). Alternatively, intravenous injection of about 1-5 mg of the oligonucleotide per kg body weight can be made into the tail vein. After about 10 to 21 days the tumors can be excised and analyzed for VEGF expression as well as by observing the weight and morphology of the tumors. Tumors and VEGF levels of mice treated with a control oligonucleotide can be compared. It is expected that the tumors and VEGF levels of the control mice will be larger than for the mice treated with the antisense oligonucleotides of the present invention.

There are several methods by which the effects of antisense oligonucleotides on VEGF expression can be monitored. At the RNA level, Northern blots can be performed. RNA can be obtained using the Guanidine Thiocyanate method of Chirgwin et al., *Biochemistry* 18, 5294 (1979). 10 ug of total RNA are electrophoresed on a 1% formaldehyde agarose gel and transferred to a charged nylon membrane (ICN Biotrans). The membranes are probed with a ³²P-labeled VEGF cDNA fragment and exposed to x-ray film.

Bioactivity can be determined by several methods, including the Miles vessel permeability assay. Miles and Miles, *J. Physiol. (Lond)*. 118, 228 (1952). Hartley guinea pigs (800g) are shaved and depilated and injected intravenously with 1.0 ml

of normal saline containing 0.5 g of Evans Blue dye per 100 ml. Subcutaneous injections (250 ul) of serum-free medium containing unknown quantities of VEGF are performed. positive (purified VEGF) and negative (normal saline) are also included in the experiment. Twenty minutes post-injection, the animals are sacrificed and the test and control sites are cut out and quantitated for extravasation of Evans Blue dye. The limit of detection for this assay is 500 pM.

Endothelial cell mitogenicity can also manifest bioactivity. In this method, human umbilical vein endothelial cells (HUVEC) are grown and maintained in EGM-UV medium (Clonetics). 1×10^4 cells are then plated in duplicate on 35 mM tissue culture dishes in 1.4 ml EBM medium (Clonetics) plus 5% heat-inactivated fetal bovine serum. Following cell attachment (about 4 hours), two dishes of cells are trypsinized, counted, and used for a starting cell number. Test samples containing unknown amounts of VEGF are then added in duplicate to the remaining dishes at day 0 and at day 2. Controls consisting of purified VEGF (positive) and PBS (negative) are also used. On day 4, the dishes of cells are trypsinized, counted and compared to the starting cell number. The limit of detection for this assay is 10 pM.

Intracellular calcium release is a third method of determining bioactivity. See, e.g., Brock and Capasso, *J. Cell Physiol.* 136, 54 (1988). Human umbilical vein endothelial cells (HUVEC) are maintained in EGM-UV medium. Cells are removed from the plate by means of EDTA and collagenase. The calcium-sensitive dye, Fura-2, is used to monitor changes in the concentration of intracellular calcium. In brief, medium containing an unknown concentration of VEGF is added to an aliquot of suspended HUVEC, pre-loaded with Fura-2. Changes in fluorescence can be measured on a Hitachi 2000 F fluorometer. Positive (histamine, thrombin) and

negative (EGTA) are also analyzed. (Thrombin and histamine activate phospholipase C in human endothelial cells via a phorbol ester sensitive pathway.) This method is extremely sensitive and has a limit of detection of 0.2 pM.

Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances, methods, and procedures described herein. Such equivalents are considered to be within the scope of this invention, and are covered by the claims presented *infra*.

The following Examples are intended to illustrate, not limit, the invention.

EXAMPLE 1

RNase H Digestion Experiment

Procedure:

The murine VEGF cDNA was subcloned into the pBluescript SK+ plasmid. ³²P-labeled RNA was transcribed as per manufacturer's specifications in the sense (T3 RNA polymerase) and the antisense (T7 RNA polymerase) orientations. Following phenol/CHCl₃ extraction and ethanol precipitation, the RNA was resuspended in T.E. Buffer (10 mM tris, pH 7.5, 1 mM EDTA, pH 8.0) and stored at -80°C. Specific activity was determined by trichloroacetic acid (TCA) precipitation. The assay conditions were as follows:

Hybridization Conditions:

100-200 ng oligonucleotide
1 ul 10X RNase H buffer
-50 mM Tris, pH 8.3
-10 mM MgCl₂
-50 mM KCl

-5 mM DTT

1X 10⁵-10⁶ dpm RNA

55°-60°C, 5 minutes

Cool to room temperature over 30 minutes

5 The RNA-oligonucleotide duplex was exposed to RNase H under the following conditions:

2 uM RNA-oligonucleotide duplex

1 ul 10X RNase H buffer

0.5 ul (0.4-0.5 units) RNase H (Pharmacia)

10 15 minutes at 37°C

15 ul of formamide/bromophenol dye mix was added and analyzed by electrophoresis on a 4% Tris-Borate-EDTA (TBE) polyacrylamide gel. Following electrophoresis, the gel was dried and exposed to x-ray film for analysis.

Oligonucleotide phosphorothioates:

15 V1: 5' - CAGAAAGTTCATGGTTTCGGA-3' (SEQ ID NO: 1)

V1 is an antisense oligonucleotide (21mer) targeted against the sequence surrounding the translational start site.

V2: 5' - TCCGAAACCATGAACTTTCTG-3' (SEQ ID NO: 10)

20 V2 is the complement (sense) oligonucleotide (21mer) to V1. It serves as a control for oligonucleotide inhibition in this experiment.

Vm: 5'-CAGCCTGGCTCACCGCCTTGG-3' (SEQ ID NO: 6)

Vm is an antisense oligonucleotide (21mer) targeted against the sequence surround the translational stop site.

R (Random): All four nucleotides at each position (21mer)

The random oligonucleotide serves as an additional oligonucleotide control for the experiment.

Analysis:

5 RNase H digestion of the VEGF sense RNA hybridized with the antisense oligonucleotides was visible. See Figure 1. The undigested probe is 980 nucleotides in length. V1 revealed the expected cleavage products of 830 and 150 nucleotides, respectively. Vm revealed expected digestion products of 665 and 315 nucleotides, respectively. Neither of the control oligonucleotides (V2, Random) resulted in any specific cleavage of the VEGF RNA. Non-specific cleavage was detected to differing
10 degrees with all the oligonucleotides.

As a control for this experiment, these oligonucleotides were hybridized to the VEGF antisense RNA and subjected to RNase H digestion. Only V2 resulted in cleavage of the RNA, resulting in cleavage products of 877 and 103 nucleotides. This result is expected as this oligonucleotide is sense in orientation.

15 This experiment shows that the antisense oligonucleotides are effective in targeting their respective sequences in the VEGF RNA, and that the resulting RNA-DNA duplex is a substrate for RNase H digestion.

EXAMPLE 2

20 Antisense Oligonucleotide Inhibition of Murine VEGF Protein Expression in COS-1 Cells as Measured by Anti-VEGF Immunoprecipitation

Procedure:

COS-1 cells stably expressing murine VEGF were grown in complete Dulbecco's Modified Eagles (DME) culture medium containing fetal bovine serum (10%), glutamine (2 mM), penicillin/streptomycin (100u/100 ug), and geneticin (200

ug/ml) to a confluency of 90%. The cells were rinsed twice with serum-free DME, and then serum-free medium containing Lipofectin, a lipid-mediated carrier, at a concentration of 10 ug/ml culture medium was added. Antisense oligonucleotides were resuspended in distilled water and added dropwise to the medium resulting in the desired concentration. Oligonucleotides were re-added (in fresh DME + 10% fetal calf serum containing no Lipofectin) after 16-20 hours. At 46 hours post initial oligonucleotide addition, the cells were rinsed in serum-free media lacking both methionine and cysteine and labeled for 4 hours in one milliliter of this medium containing 150-200 uCi ³⁵S-Translabel (ICN). The labeled medium was collected, centrifuged to remove any cells and/or debris, and frozen at -80°C.

Labeled protein was precipitated in the presence of BSA (100 ug) and TCA (5%). The precipitated protein was captured on a glass fiber filter and counts were determined by means of a scintillation counter. Equal TCA-precipitable counts were immunoprecipitated overnight at 4°C in the presence of a polyclonal anti-VEGF (human) antibody. This human antibody has been shown to cross-react with the murine VEGF protein. The antibody-VEGF complex was removed from the immunoprecipitation solution using protein A sepharose. The protein A sepharose was washed 3X in a solution containing 10 mM Tris, pH 8.0, 140 mM NaCl, 0.1% BSA, 0.1% Triton X-100, 0.01% Sodium Azide, and resuspended in 2X SDS PAGE loading buffer + 7 mM DTT. The immunoprecipitated samples were electrophoresed on a 5.5%/12.5% SDS polyacrylamide gel, enhanced using Entensify solution (New England Nuclear), dried, and exposed to film.

Oligonucleotides phosphorothioates:

V1: 5'-CAGAAAGTTCATGGTTTCGGA-3' (SEQ ID NO: 1)

V1 is a antisense oligonucleotide (21mer) targeted against the sequence surrounding the translational start site.

V2: 5' - TCCGAAACCATGA~~ACTTT~~CTG-3' (SEQ ID NO 10)

5 V2 is the complement (sense) oligonucleotide (21mer) to V1. It serves as a control for oligonucleotide inhibition in this experiment.

Vm: 5'-CAGCCTGGCTC~~ACCGC~~CTTGG-3' (SEQ ID NO 6)

Vm is an antisense oligonucleotide (21mer) targeted against the sequence surrounding the translational stop site.

R (Random): All four nucleotides at each position (21 mer)

10 The random oligonucleotide serves as an additional oligonucleotide control for the experiment.

Analysis:

15 VEGF protein migrates as a monomer of 23 kDa under reduced conditions in an SDS polyacrylamide gel. In antisense oligonucleotide inhibition studies, it is important to show an inhibition of the active molecule, the protein. VEGF is a secreted protein, and immunoprecipitation of the protein is the most efficient means of detection. The results of this experiment (Figure 2) show antisense oligonucleotide inhibition of murine VEGF by Vm, an oligonucleotide targeting sequences surrounding the translational stop site. Two control oligonucleotides (V2 and
20 Random) as well as another antisense oligonucleotide (V1) do not inhibit VEGF protein expression. This final result is important as it reveals that not all antisense oligonucleotides are effective as inhibitors of VEGF.

EXAMPLE 2**Antisense Oligonucleotide Inhibition of Murine VEGF Protein Expression
in NB41 Cells as Measured by Anti-VEGF Immunoprecipitation****Procedure:**

5 NB41, a murine neuroblastoma cell line which endogenously expresses murine VEGF, were grown in complete Dulbecco's Modified Eagles (DME) culture medium containing fetal bovine serum (10%), glutamine (2 mM), penicillin/streptomycin (100u/100 ug), to a confluency of 90%. The cells were refed immediately before the
10 experiment with new culture medium. Oligonucleotides were resuspended in phosphate-buffered sale (PBS) and mixed with DOTAP (Boehringer-Manheim), a newly formulated lipofection reagent (2.5 ug/ml of culture medium), at the desired concentration. Oligonucleotides were readded (in fresh DME + 10% fetal calf serum containing no DOTAP) after 16-20 hours. At 36-40 hours post initial oligonucleotide addition, the cells were rinsed in serum-free media lacking both methionine and
15 cysteine and labeled for 4 hours in one milliliter of this medium containing 150-200 uCi ³⁵S-Translabel (ICN). The labeled medium was collected, centrifuged to remove any cells and/or debris, and frozen at -80°C.

Labeled protein was precipitated in the presence of BSA (100 ug) and TCA (5%). The precipitated protein was captured on a glass fiber filter and counts were
20 determined by means of a scintillation counter. Equal TCA-precipitable counts were immunoprecipitated overnight at 4°C in the presence of a polyclonal anti-VEGF (human) antibody. This human antibody cross-reacts with the murine VEGF protein. The antibody-VEGF complex was removed from the immunoprecipitation solution using protein A sepharose. The protein A sepharose was washed 3X in a solution
25 containing 10 mM Tris, pH 8.0, 140 mM NaCl, 0.1% BSA, 0.1% Triton X-100, 0.01%

Sodium azide and resuspended in 2X SDS PAGE loading buffer + 7 mM DTT. The immunoprecipitated samples were electrophoresed on a 5.5%/12.5% SDS polyacrylamide gel, enhanced using Entensify solution (New England Nuclear), dried, and exposed to film.

5 Oligonucleotides phosphorothioates:

JG-1: 5'-CAACGGTGACGATGATGGCA-3' (SEQ ID NO: 9)

JG1 is an antisense oligonucleotide (20mer) targeted against sequences in the 3' untranslated region of the murine VEGF molecule.

JG-3: 5'-TCGCGCTCCCTCTCTCCGGC-3' (SEQ ID NO: 8)

10 JG-3 is an antisense oligonucleotide (20mer) targeted against sequences in the 5' untranslated region of the murine VEGF molecule.

JG-4: 5'-CATGGTTTCGGAGGGCGTC-3' (SEQ ID NO: 3)

JG-4 is an antisense oligonucleotide (19mer) targeted against sequences 5' to and containing the ATG of the translational start site of the murine VEGF molecule.

15 JG-5: 5'-CAAGAGAGCAGAAAGTTCAT-3' (SEQ ID NO: 7)

JG-5 is an antisense oligonucleotide (20mer) targeted against sequences containing the ATG and extending into the coding region of the murine VEGF molecule.

JG-6: 5'-CACCCAAGAGAGCAGAAAGT-3' (SEQ ID NO: 4)

20 JG-6 is an antisense oligonucleotide (20mer) targeted against sequences containing codons 2-7 of the murine VEGF molecule.

JG-7: 5'-TCGTGGGTGCAGCCTGGGAC-3' (SEQ ID NO: 5)

JG-7 is an antisense oligonucleotide (20mer) targeted against sequences containing codons 24-29 of the murine VEGF molecule.

Vm: 5'-CAGCCTGGCTCACC GCCTTGG-3' (SEQ ID NO: 6)

Vm is an antisense oligonucleotide (21mer) targeted against the sequence surrounding the translational stop site.

Analysis:

5 This experiment tested the activity of several oligonucleotides in inhibiting VEGF protein expression. See Figure 3. Several of these oligonucleotides (i.e., JG-4, JG-6, JG-7) inhibit the production of VEGF protein. Other oligonucleotides (i.e., JG-1, JG-3, JG-5) have no effect on VEGF protein production. This experiment also reconfirms the inhibition seen with Vm in the previous experiment.

10

EXAMPLE 4

In Vivo Inhibition of VEGF Expression
and Tumor Growth Rate in Murine Systems

15 VEGF expression and tumor growth rate inhibition may be demonstrated in the following manner. Inject tumor cell lines that are known to express VEGF subcutaneously into nude mice. Tumor formation will generally be observed within 2-3 weeks. Administer about 2.5 mg of the JG-4 antisense oligonucleotide phosphorothioate per kg body weight by intravenous injection into the tail veins of a group of 15 nude mice suffering from tumor angiogenesis. Similarly inject a control antisense oligonucleotide phosphorothioate into a group consisting of an equal number of nude mice. Follow the mice for 21 days. Excise the tumors and analyze them for weight and morphology as well as by immunohistochemical methods for VEGF expression. VEGF expression and tumor growth rate are expected to be lower in those mice receiving injections of JG-4 than in those receiving injection of the control oligonucleotide.

20

Similar results are expected with the JG-6, JG-7 and the Vm antisense oligonucleotide phosphorothioates.

EXAMPLE 5

Inhibition of VEGF Expression in Human Cells

5 Inhibition of VEGF expression in human cells may be shown in the following manner. Grow MNNG-HOS (N-methyl-N-nitro-N-nitrosoguanidine-induce osteogenic sarcoma) cells in complete Dulbecco's Modified Eagles (DME) culture medium containing fetal bovine serum (10%), glutamine (2 mM), penicillin/streptomycin (100
10 u/100 ug), to a confluency of 90%. Refeed the cells immediately before the experiment with new culture medium. Resuspend oligonucleotides in phosphate-buffered saline (PBS) and mix with DOTAP (Boehringer-Manheim), a newly formulated lipofection reagent (2.5 ug/ml of culture medium), at the desired concentration. Readd oligonucleotides (in fresh DME + 10% fetal calf serum containing no DOTAP) after 16-20 hours. At 36-40 hours post initial oligonucleotide
15 addition, rinse the cells in serum-free media lacking both methionine and cysteine and label for 4 hours in one milliliter of this medium containing 150-200 uCi ³⁵S-Translabel (ICN). Collect the labeled medium, centrifuge to remove any cells and/or debris, and freeze at -80°C.

 Precipitate labeled protein in the presence of BSA (100 ug) and TCA (5%).
20 Capture the precipitated protein on a glass fiber filter and determine counts by means of a scintillation counter. Immunoprecipitate equal TCA-precipitable counts overnight at 4°C in the presence of a polyclonal anti-VEGF (human) antibody. Remove the antibody-VEGF complex from the immunoprecipitation solution using protein A sepharose. Wash the protein A sepharose 3X in a solution containing 10

mM Tris, pH 8.0, 140 mM NaCl, 0.1% BSA, 0.1% Triton X-100, 0.01% Sodium azide and resuspended in 2X SDS PAGE loading buffer + 7 mM DTT. Electrophorese the immunoprecipitated samples on a 5.5%/12.5% SDS polyacrylamide gel, enhance using Entensify solution (New England Nuclear), dry, and expose to film.

5 Oligonucleotide phosphorothioates:

5'-TCCGAAACCATGAACTTTCTG-3' (SEQ ID NO: 15)

This is an antisense oligonucleotide (21mer) targeted against sequences in the 3' untranslated region of the human VEGF molecule.

5'-TCGCGCTCCCTCTCCGGCTC-3' (SEQ ID NO: 16)

10 This is an antisense oligonucleotide (20mer) targeted against sequences in the 5' untranslated region of the human VEGF molecule.

5'-CATGGTTTCGGAGGCCCGA-3' (SEQ ID NO 12)

This is an antisense oligonucleotide targeted to the sequence 5' to and containing the ATG of the translational start site of the human VEGF molecule.

15 5'-CAAGACAGCAGAAAGTTCAT-3' (SEQ ID NO: 14)

This is an antisense oligonucleotide (20mer) targeted against sequences containing ATG and coding region of the human VEGF molecule.

5'-CACCCAAGACAGCAGAAAGT-3' (SEQ ID NO: 13)

20 This is an antisense oligonucleotide (20mer) targeted against sequences containing codons 2-7 of the human VEGF molecule.

5'-CCATGGGTGCAGCCTGGGAC-3' (SEQ ID NO: 17)

This is an antisense oligonucleotide (20mer) targeted against sequences containing codons 24-29 of the human VEGF molecule.

5'-CTGCCCCGGCTCACCGCCTCGG-3' (SEQ ID NO: 11)

This is an antisense oligonucleotide (21mer) targeted against the sequence surrounding the translational stop site.

Analysis:

5 This experiment tests the activity of several oligonucleotides in inhibiting VEGF protein expression. Several of these oligonucleotides, SEQ ID NOs 11-13 and 17 are expected to inhibit the production of the VEGF protein. Other oligonucleotides SEQ ID NOs 14-16 are expected to have no effect on VEGF protein production.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Hybridon, Inc.

5

(ii) TITLE OF INVENTION: Antisense Oligonucleotides That Inhibit
VEGF Expression

(iii) NUMBER OF SEQUENCES: 17

10

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Michael S. Greenfield

(B) STREET: 10 S. Wacker Drive Suite 3000

(C) CITY: Chicago

15

(D) STATE: Illinois

(E) COUNTRY: U.S.A.

(F) ZIP: 60606

(v) COMPUTER READABLE FORM:

20

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

30

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Greenfield, Michael S.

(B) REGISTRATION NUMBER: P-37,142

(C) REFERENCE/DOCKET NUMBER: 93,538

35

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (312)715-1000

(B) TELEFAX: (312)715-1234

(2) INFORMATION FOR SEQ ID NO:1:

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

45

(D) TOPOLOGY: linear

(iii) HYPOTHETICAL: NO

28

(iv) ANTI-SENSE: YES

(ix) FEATURE:

(A) NAME/KEY: misc_feature

5 (B) LOCATION: 1..21

10 (D) OTHER INFORMATION: /note = "phosphorothioate internucleotide linkages"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

15 CAGAAAGTTC ATGGTTTCGG A 21

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

20 (A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

25 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(ix) FEATURE:

(A) NAME/KEY: misc_feature

30 (B) LOCATION: 1..21

(D) OTHER INFORMATION: /note = "phosphorothioate internucleotide linkages"

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CAGCCTGGCT CACCGCCTTG G 21

(2) INFORMATION FOR SEQ ID NO:3:

40 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

45 (D) TOPOLOGY: linear

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

29

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION: 1..21

5 (D) OTHER INFORMATION: /note = "phosphorothioate internucleotide
linkages"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

10 CATGGTTTCG GAGGGCGTC

19

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

15 (A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

20 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(ix) FEATURE:

25 (A) NAME/KEY: misc_feature

(B) LOCATION: 1..20

(D) OTHER INFORMATION: /note = "phosphorothioate internucleotide
linkages"

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CACCCAAGAG AGCAGAAAGT

20

(2) INFORMATION FOR SEQ ID NO:5:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

40 (D) TOPOLOGY: linear

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

45

(ix) FEATURE:

(A) NAME/KEY: misc_feature

30

(B) LOCATION: 1..20

(D) OTHER INFORMATION: /note = "phosphorothioate internucleotide linkages"

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TCGTGGGTGC AGCCTGGGAC

20

(2) INFORMATION FOR SEQ ID NO:6:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

15

(D) TOPOLOGY: linear

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

20

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION: 1..20

25

(D) OTHER INFORMATION: /note = "phosphorothioate internucleotide linkages"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

30

CAGCCTGGCT CACCGCCTTG G

21

(2) INFORMATION FOR SEQ ID NO:7:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

40

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

45

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION: 1..20

(D) OTHER INFORMATION: /note = "phosphorothioate internucleotide linkages"

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CAAGAGAGCA GAAAGTTCAT

20

(2) INFORMATION FOR SEQ ID NO:8:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

15

(D) TOPOLOGY: linear

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

20

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION: 1..20

25 linkages" (D) OTHER INFORMATION: /note = "phosphorothioate internucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

30 TCGCGCTCCC TCTCTCCGGC

20

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

35

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

40

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(ix) FEATURE:

45

(A) NAME/KEY: misc_feature

(B) LOCATION: 1..20

(D) OTHER INFORMATION: /note = "phosphorothioate internucleotide linkages"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CAACGGTGAC GATGATGGCA

20

5 (2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(iii) HYPOTHETICAL: NO

15 (iv) ANTI-SENSE: NO

(ix) FEATURE:

- 20 (A) NAME/KEY: misc_feature
(B) LOCATION: 1..21
(D) OTHER INFORMATION: /note = "phosphorothioate internucleotide
linkages"

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

TCCGAAACCA TGAAC TTTCT G

21

30 (2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(iii) HYPOTHETICAL: YES

40 (iv) ANTI-SENSE: YES

(ix) FEATURE:

- 45 (A) NAME/KEY: misc_feature
(B) LOCATION: 1..21
(D) OTHER INFORMATION: /note = "phosphorothioate internucleotide
linkages"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CTGCCCCGGCT CACCGCCTCG G

21

5 (2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(iii) HYPOTHETICAL: YES

15 (iv) ANTI-SENSE: YES

(ix) FEATURE:

- 20 (A) NAME/KEY: misc_feature
(B) LOCATION: 18..20
(D) OTHER INFORMATION: /note = "phosphorothioate internucleotide
linkages"

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CATGGTTTCGGAGGCCCGA

20

(2) INFORMATION FOR SEQ ID NO:13:

30 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

35

(iii) HYPOTHETICAL: YES

(iv) ANTI-SENSE: YES

40 (ix) FEATURE:

- (A) NAME/KEY: misc_feature
(B) LOCATION: 1..20
(D) OTHER INFORMATION: /note = "phosphorothioate internucleotide
linkages"

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

34

CACCCAAGA CAGCAGAAAGT

20

(2) INFORMATION FOR SEQ ID NO:14:

5 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

10

(iii) HYPOTHETICAL: YES

(iv) ANTI-SENSE: YES

15 (ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1..20
- (D) OTHER INFORMATION: /note = "phosphorothioate internucleotide linkages"

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CAAGACAGCA GAAAGTTCAT

20

25

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

30

(iii) HYPOTHETICAL: YES

35

(iv) ANTI-SENSE: YES

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1..21
- (D) OTHER INFORMATION: /note = "phosphorothioate internucleotide linkages"

40

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

TCCGAAACCA TGAAC TTTCT G

21

35

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

10 (iii) HYPOTHETICAL: YES

(iv) ANTI-SENSE: YES

(ix) FEATURE:

- 15 (A) NAME/KEY: misc_feature
(B) LOCATION: 1..20
(D) OTHER INFORMATION: /note = "phosphorothioate internucleotide
linkages"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

20 TCGCGCTCCC TCTCCGGCTC 20

(2) INFORMATION FOR SEQ ID NO:17:

25 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

30 (iii) HYPOTHETICAL: YES

(iv) ANTI-SENSE: YES

35 (ix) FEATURE:

- (A) NAME/KEY: misc_feature
(B) LOCATION: 1..20
(D) OTHER INFORMATION: /note = "phosphorothioate internucleotide
linkages"

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

CCATGGGTGC AGCCTGGGAC 20

What is claimed is:

1. A VEGF-inhibiting antisense oligonucleotide complementary to mRNA or double-stranded DNA that express mammalian VEGF.
2. A VEGF-inhibiting antisense oligonucleotide according to claim 1, wherein
5 the antisense oligonucleotide anneals to a coding sequence of mRNA or double-stranded DNA that express VEGF.
3. A VEGF-inhibiting antisense oligonucleotide according to claim 2, wherein the coding sequence contains VEGF codons 2-7 or 24-29.
4. A VEGF-inhibiting antisense oligonucleotide according to claim 1, wherein
10 the antisense oligonucleotide anneals to the start or stop sequence of mRNA or double-stranded DNA that express VEGF.
5. A VEGF-inhibiting antisense oligonucleotide according to claim 1, wherein the oligonucleotide is stabilized.
6. A VEGF-inhibiting antisense oligonucleotide according to claim 5, wherein
15 the oligonucleotide is stabilized by methylphosphonothioate internucleotide linkages, phosphorothioate internucleotide linkages, methylphosphonate internucleotides linkages, phosphoramidate internucleotide linkages, a 3' end cap, or a 3' hair-pin loop structure.
7. A VEGF-inhibiting antisense oligonucleotide according to claim 1, wherein the oligonucleotide is a mixed phosphate backbone oligonucleotide having an internal
20 sequence that activates RNase H and that is flanked on one or both sides by sequences that are unable to active RNase H.
8. An antisense oligonucleotide having the formula 5'-CAGCCTGGCTCACCGCCTTGG-3' (SEQ ID NO 6).
9. An antisense oligonucleotide having the formula 5'-

CATGGTTTCGGAGGGCGTC-3' (SEQ ID NO 3).

10. An antisense oligonucleotide having the formula 5'-
CACCCAAGAGAGCAGAAAGT-3' (SEQ ID NO 4).

11. An antisense oligonucleotide having the formula 5'-
5 TCGTGGGTGCAGCCTGGGAC-3' (SEQ ID NO 5).

12. An antisense oligonucleotide having the formula 5'-
CTGCCCCGGCTCACCGCCTCGG-3' (SEQ ID NO: 11).

13. An antisense oligonucleotide having the formula 5'-
CATGGTTTCGGAGGCCCGA-3' (SEQ ID NO: 12).

10 14. An antisense oligonucleotide having the formula 5'-
CACCCAAGACAGCAGAAAGT-3' (SEQ ID NO; 13).

15. An antisense oligonucleotide having the formula 5'-
CCATGGGTGCAGCCTGGGAC-3' (SEQ ID NO:17).

16. A method for inhibiting VEGF expression comprising providing an
15 effective VEGF expression-inhibiting amount of an antisense oligonucleotide
complementary to VEGF mRNA.

17. A method for inhibiting VEGF expression according to claim 16, wherein
the oligonucleotide anneals to a coding sequence of the VEGF mRNA.

18. A method for inhibiting VEGF expression according to claim 17, wherein
20 the coding sequence of the VEGF mRNA includes codons 2-7 or 24-29.

19. A method for inhibiting VEGF expression according to claim 16, wherein
the oligonucleotide binds to the start or stop sequence of VEGF mRNA.

20. A method for inhibiting VEGF expression according to claim 16, wherein
the oligonucleotide is stabilized.

21. A method for inhibiting VEGF expression according to claim 20, wherein the oligonucleotide is stabilized by methylphosphonothioate internucleotide linkages, phosphorothioate internucleotide linkages, methylphosphonate internucleotides linkages, phosphoramidate internucleotide linkages, a 3' end cap, or a 3' hair-pin loop structure.

5 22. A method for inhibiting VEGF expression according to claim 16, wherein the oligonucleotide is a mixed phosphate backbone oligonucleotide having an internal sequence that activates RNase H and that is flanked on one or both sides by sequences that are unable to active RNase H.

23. A method according to claim 16, wherein the antisense oligonucleotide is
10 chosen from the group consisting of the oligonucleotide phosphorothioates 5'-CAGCCTGGCTCACCGCCTTGG-3' (SEQ ID NO 6), 5'-CATGGTTTTCGGAGGGCGTC-3' (SEQ ID NO 3), 5'-CACCCAAGAGAGCAGAAAGT-3' (SEQ ID NO 4), 5'-TCGTGGGTGCAGCCTGGGAC-3' (SEQ ID NO 5) and mixtures thereof.

15 24. A method according to claim 16, wherein the antisense oligonucleotide is chosen from the group consisting of the oligonucleotide phosphorothioates 5'-CTGCCCCGGCTCACCGCCTCGG-3' (SEQ ID NO: 11), 5'-CATGGTTTTCGGAGGCCCGA-3' (SEQ ID NO: 12), 5'-CACCCAAGACAGCAGAAAGT-3' (SEQ ID NO; 13), and 5'-
20 CCATGGGTGCAGCCTGGGAC-3' (SEQ ID NO:17).

25. A method for the treatment of abnormal angiogenesis comprising administration of an effective VEGF expression-inhibiting amount of an antisense oligonucleotide complementary to VEGF mRNA.

26. A method for inhibiting VEGF expression according to claim 25, wherein

the oligonucleotide anneals to a coding sequence of the VEGF mRNA.

27. A method for inhibiting VEGF expression according to claim 26, wherein the coding sequence of the VEGF mRNA includes codons 2-7 or 24-29.

28. A method for inhibiting VEGF expression according to claim 25, wherein
5 the oligonucleotide anneals to the start or stop sequence of VEGF mRNA.

29. A method for inhibiting VEGF expression according to claim 25, wherein the oligonucleotide is stabilized.

30. A method for inhibiting VEGF expression according to claim 29, wherein the oligonucleotide is stabilized by methylphosphonothioate internucleotide linkages,
10 phosphorothioate internucleotide linkages, methylphosphonate internucleotides linkages, phosphoramidate internucleotide linkages, a 3' end cap, or a 3' hair-pin loop structure.

31. A method for inhibiting VEGF expression according to claim 25, wherein the oligonucleotide is a mixed phosphate backbone oligonucleotide having an internal sequence that activates RNase H and that is flanked on one or both sides by sequences
15 that are unable to active RNase H.

32. A method for inhibiting VEGF expression according to claim 25, wherein the antisense oligonucleotide is chosen from the group consisting of 5'-CAGCCTGGTTCACCGCCTTGG-3' (SEQ ID NO 6), 5'-CATGGTTTCGGAGGGGCGTC-3' (SEQ ID NO 3), 5'-
20 CACCCAAGAGAGCAGCAGAAAGT-3' (SEQ ID NO 4), 5'-TCGTGGGTGCAGCCTGGGAC-3' (SEQ ID NO 5) and mixtures thereof.

33. A method for inhibiting VEGF expression according to claim 25, wherein the antisense oligonucleotide is chosen from the group consisting of 5'-CTGCCCCGGCTCACCGCCTCGG-3' (SEQ ID NO: 11), 5'-

CATGGTTTCGGAGGCCCGA-3' (SEQ ID NO: 12), 5'-
CACCCAAGACAGCAGAAAGT-3' (SEQ ID NO: 13), and 5'-
CCATGGGTGCAGCCTGGGAC-3' (SEQ ID NO:17).

34. A pharmaceutical composition comprising an effective VEGF expression-
5 inhibiting amount of an antisense nucleotide.

35. A pharmaceutical composition according to claim 34, wherein the
oligonucleotide anneals to a coding sequence of the VEGF mRNA.

36. A pharmaceutical composition according to claim 35, wherein the coding
sequence of the VEGF mRNA includes codons 2-7 or 24-29.

10 37. A pharmaceutical composition according to claim 34, wherein the
oligonucleotide anneals to the start or stop sequence of VEGF mRNA.

38. A pharmaceutical composition according to claim 34, wherein the
oligonucleotide is stabilized.

39. A pharmaceutical composition according to claim 34, wherein the
15 oligonucleotide is stabilized by methylphosphonothioate internucleotide linkages,
phosphorothioate internucleotide linkages, methylphosphonate internucleotides linkages,
phosphoramidate internucleotide linkages, a 3' end cap, or a 3' hair-pin loop structure.

40. A pharmaceutical composition according to claim 34, wherein the
oligonucleotide is a mixed phosphate backbone oligonucleotide having an internal
20 sequence that activates RNase H and that is flanked on one or both sides by sequences
that are unable to active RNase H.

41. A pharmaceutical composition according to claim 34, wherein the antisense
oligonucleotide is chosen from the group consisting of 5'-
CAGCCTGGCTCACCGCCTTGG-3' (SEQ ID NO 6), 5'-

41

CATGGTTTCGGAGGGGCGTC-3' (SEQ ID NO 3), 5'-
CACCCAAGAGAGCAGCAGAAAGT-3' (SEQ ID NO 4), 5'-
TCGTGGGTGCAGCCTGGGAC-3' (SEQ ID NO 5) and mixtures thereof.

42. A pharmaceutical composition according to claim 34, wherein the antisense
5 oligonucleotide is chosen from the group consisting of 5'-
CTGCCCCGGCTCACCGCCTCGG-3' (SEQ ID NO: 11), 5'-
CATGGTTTCGGAGGGCCCGA-3' (SEQ ID NO: 12), 5'-
CACCCAAGACAGCAGAAAGT-3' (SEQ ID NO: 13), and 5'-
CCATGGGTGCAGCCTGGGAC-3' (SEQ ID NO:17).

10




FIG. 1/3




FIG. 2/3




FIG. 3/3

WIPO 47 pages

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.